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Total HIV DNA as guidance for simplification strategies Sofie Rutsaert Gent University, Gent, Belgium
Although a triple therapy is the recommended initial treatment for HIV-patients, therapy simplification by reducing the number of drugs is being explored. Fewer drugs can reduce cost, avoid drug-drug interactions, improve tolerability and reduce toxicity for a lifelong treatment. The efficacy of mono and dual therapy has been explored in numerous clinical trials and the applicability depends on the individual patient and regimen. When a simplified regimen is applicable, total HIV DNA which reflects the number of infected cells in treated patients can aid in selecting eligible patients. A significant higher level of HIV DNA is observed in patients who fail virologically while on a simplified regimen, when compared to patients who maintained an undetectable viral load. This has been observed in different regimens (DRV/r monotherapy, RAL+ETR.) and indicates the validity of total HIV DNA in guiding the treatment strategies. However, to be clinical useful, this observation will have to be confirmed in a long-term and in other regimens, such as DTG/3TC or DTG/RPV dual therapy. Traditional methods for tracking disease-carrying mosquitoes are hitting budget constraints as the scales over which they must be implemented grow exponentially. Citizen science offers a set of innovative tools for public health management, allowing sustained and flexible data collection while facilitating public participation in problem solving. There is increasing evidence that combining citizen scientist data with other sources of information significantly improves our knowledge in a given area. In particular, once we adjust for sampling bias, vector data obtained through the Mosquito Alert citizen science program has almost the same quality and predictive power as the one obtained from traditional surveillance. We are now further integrating vector data with epidemiological and social relevant data into a digital platform to augment the information already available from public health sources and provide risk models and key information to public health authorities at near real-time. The scientific exploitation of citizen science programs and big data solutions, should effectively help to reduce the presence of targeted mosquitoes and minimize current health threats.
S4
Climate change, socio-political changes and emerging pandemics Current treatments against hepatitis B with nucleos(t)ides entecavir or tenofovir used orally provide sustained suppression of HBV replication and clinical benefit in most HBsAg+ people. However, HBV rebound generally occurs upon drug discontinuation due to persistence of genomic HBV reservoirs as episomic cccDNA and chromosomic integrated HBV-DNA. New drugs that target distinct steps of the HBV life cycle are been developed, including inhibitors of viral entry, new polymerase inhibitors, capsid and assembly inhibitors, virus release blockers, and disruptors of cccDNA formation and transcription. The achievement of a 'functional cure' for chronic HBV infection, with sustained HBsAg clearance and undetectable viremia once medications are stopped, represents the next step in the pace towards HBV elimination.
S6
The emergence of NASH issues after cure of hepatitis C Lawrence Serfaty Hautepierre Hospital, Strasbourg, France Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease with an estimated prevalence worldwide ranging from 25% to 45%, concomitantly with the epidemic of obesity, type 2 diabetes and metabolic syndrome. While pure liver steatosis is considered benign with low risk of progression to more severe liver disease, approximately 20% of NAFLD patients have histologic signs of necroinflammation with or without fibrosis, indicating nonalcoholic steatohepatitis (NASH) , and are at risk of developing cirrhosis, end-stage liver failure and hepatocellular carcinoma. Out of liverrelated complications, it has been suggested that NAFLD may promote cardiovascular disease, maligancy and chronic kidney disease. The persistence of comorbidities such as obesity, type 2 diabetes and NAFLD, after the cure of HCV infection may explain the progression of liver disease in some patients. In the French Cirvir cohort of HCV cirrhotic patients, the presence of metabolic syndrome was associated with a significant increase in the incidence of hepatocellular carcinoma in SVR patients. In this setting, comorbidities should be managed once HCV infection is cured. Lifestyle interventions, control or treatment of diabetes should be encouraged. In case of persistent fibrosis, new molecules targeting NASH and/or fibrosis should be evaluated.
S7
Lyme disease: where is the controversy?
Christian Perronne Raymond Poincaré Hopsital, Garches, France Lyme disease is one of the most important controversy in medicine history. Despite its previous description in Europe at the end of the 19 th century and at the beginning of the 20 th century, it has been officially described in the USA in the early seventies. A small group of experts from the Infectious Diseases Society of America (IDSA) described the disease on expert opinion basis and not on scientific data. They declared and published that the disease was rare, easily diagnosed with very efficient serologic tests, easily cured with 2 or 3 weeks of antibiotic treatment, and that a chronic form of the disease did not exist. However, the medical literature, including articles in major journals, is rich in publications showing that the causative agent, Borrelia burgdorferi, could be isolated by culture or PCR from seronegative patients and providing evidence that Borrelia sp. can persist in blood and tissues despite several weeks or months of antibiotic treatment. As emphasized by the ECDC in April 2016, Lyme serology is quite impossible to calibrate properly. The cause is the fact that, in absence of a diagnostic gold standard, it is impossible to define for sure populations of patients or controls. A meta-analysis published at the end of 2016 showed that the sensitivity of Lyme serology was less than 60%. Moreover, serologic tests only exist for one strain of Borrelia in North America and 3 strains in Europe. There is no test available for the numerous Borrelia sp. found in ticks and already isolated from patients. We know from publications that patients suspected to have a chronic Lyme disease may harbor other bacteria such as Anaplasma, Bartonella (including strains previously unknown in humans), Ehrlichia, Neoerlichia, Rickettsia, Coxiella, Francisella, etc. They can also harbor parasites such as Babesia sp. Some labs, including veterinary labs, have developed promising PCR methods. The consequence of the lack of reliable diagnostic tests in routine for Lyme and co-infections is the suffering and the wandering of millions of patients in the world, rejected by the medical community and often ending in psychiatry wards. Not a single controlled randomized study has evaluated the efficacy of prolonged anti-infectious treatment (longer than 3 months) on the chronic form of the disease. Despite the important underestimation of the incidence measured on serology, the official incidence of the disease is rising in many countries in America and Europe in huge proportions (such as 10 fold increase or more in a decade). Research funding is urgently needed to better manage this public health threatening infectious disease.
S8
HIV and lungs at the time of effective ART Jean-Pierre Routy McGill University, Montreal, Canada
People living with HIV receiving ART are living longer and experiencing reduced AIDS-related events. However, increases in non-AIDS related conditions, such as certain cancers, have accompanied these therapeutic advances. Smoking, modified microbiota combined with immunosuppression increase the risk for lung cancer in this population. Prevention and treatment remain a challenge due to life style issues, including marijuana usage and potential interactions with ART and anticancer therapies, to comorbidities. Lung cancers express higher PD-L1 levels with increased immune infiltration, supporting participation in clinical trials assessing immune checkpoint inhibitors. Furthermore, these new therapies with checkpoint inhibitors may also contribute to reduce HIV reservoir, paving the way for HIV eradication.
S9

New biomarkers of latency
Christina Psomas Montpellier, France
The 'Holy Grail' of the HIV world is to identify a marker that could characterize latent cells. Indeed, latently infected long-lived memory CD4+ T cells are the major obstacle in order to achieve a sterilizing cure. They not only remain invisible to the immune system, but are also unattainable by both antiretroviral therapy and cure approaches because of lack of targeting specificity of 'shock and kill' strategies involving reactivation of the dormant virus. In a recent Nature article, Descours et al. (Nature 2018; 543: 564-567) reported that CD32a, the low-affinity receptor for the immunoglobulin G Fc fragment may be a cell surface signature of CD4+ T cells harbouring latent HIV genomes. Since then, the relationship between CD32a expression and HIV persistence has been strongly debated by other groups. Will this biomarker help us address the mystery surrounding in vivo latent reservoirs and develop a cure-focused HIV diagnostic in the near future?
S10
Immunotherapies and immune check-points
For a very large spectrum of malignancies, the use of PD-1 or PDL-1 and/or CTL-4 immune-checkpoint-inhibitor antibody (ICI) that restores antitumor immunity by disrupting PD-1/PDL-1 or CTL-4-mediated signaling has demonstrated a real significant interest in terms of efficacy compared with conventional chemotherapy but also a significant toxicity profile. Regarding the results of several phase 3 showing a significant impact upon overall survival compared with conventional chemotherapy, some ICI (ipilimumab, nivolumab, pembrolizumab, atezolizumab, darvelumab) has already got FDA and/or EMA approval providing new standard of care for some cancer patients. PD-1 receptor for instance, which is expressed on activated T cells, in link with ligands PDL-1 and PDL-2 expressed in tumor cells, remains the cornerstone for the rational for the development of such drugs. For sure, like other antitumor therapies, ICI can cause some sides effects and for the majority of them we have improved in their understanding and some recommendations have already been published to take care of them. Moreover, a new strategy in immunotherapy field has also recently emerged: the CAR T-cells. In HIV setting, cancer remains the leading cause of morbidity and mortality. PD-1 expression on HIV-specific T cells is associated with T cell exhaustion and some preclinical studies have suggested that blocking the PD-1/PDL-1 axis with monoclonal antibodies would be of highest interest during HIV associated lymphoma and may be other cancers. As HIV infected patients are generally excluded from the clinical trials in oncology, we need some data about tolerance and efficacy of using ICI in HIV infected patients with cancer.
S11
HPV vaccination: use in prevention and in cure Deborah Konopnicki Saint Pierre University Hospital, Brussels, Belgium Human papillomaviruses (HPV) are responsible for the development of condyloma and cancer in the ano-genital and oropharyngal areas. These lesions are more frequent and more difficult to treat in HIV-positive persons. Preventive vaccines against HPV are available since a decade and their use in primary and secondary prophylaxis should be proposed to HIV-positive patients. Issues on vaccines schedules, costs and HPV genotypes coverage will be presented. Meanwhile, other therapeutical vaccines are currently under development and phase II studies will be discussed.
S12
Cohorts
Caroline Sabin Royal Free Campus, London, UK
Cohort studies analyze a group of individuals over time until the development of some events. Even if this study approach is often used to describe the association between exposure to one or more factors and the risk of the event occurring, the interpretation of results from cohort studies is often limited by the presence of one or more biases. For this reason, randomized controlled trials are believed to provide the most solid evidence when determining causal associations. Nevertheless, with due care in this study approach, the impact of some of these biases cannot be reduced.
S13
The future of digital games for HIV prevention and care
Lynn Fiellin Yale Center for Health and Learning Games, New Haven, CT, USA The purpose of this presentation is to share two digital games that have been developed and evaluated by the play2PREVENT Lab at Yale that focus on risk reduction and HIV prevention and HIV testing and counseling. The first game, playForward: Elm City Stories (playForward), is a 2-D graphic novel style interactive videogame that focuses on adolescents acquiring and practicing skills to reduce risk behaviors and gain knowledge and healthier attitudes and intentions with the ultimate goal of HIV prevention. The impact of PlayForward on at-risk adolescents was recently rigorously evaluated through a full-scale randomized controlled trial and demonstrated a significant and persistent positive effect on behavioral antecedents/health outcomes that are critical for HIV prevention. A follow-up game, playForward: Test! was adapted from the original game to have a greater focus on HIV testing and counseling. This game has been pilot-tested and is undergoing further expansion and then will be evaluated through an RCT.
S14
PrEP in Europe: where are we?
Rosalind Coleman Joint United Nations Program on HIV/AIDS, Geneva, Switzerland
The picture of PrEP access in Europe is highly diverse and rapidly changing. The rising number of new infections in different populations across the region demands a fresh HIV prevention approach that includes the focussed and appropriate use of PrEP. This talk will cover various national programmes and other ongoing PrEP projects; estimated numbers of people on PrEP and gaps in these data; costing and payment options; and the rise of buyers' clubs and other PrEP activism. The various stumbling blocks to PrEP, such as the possible rise of other sexually transmitted infections, the perceived competition for resources with HIV treatment and the concerns about augmentation of antiretroviral resistance will be addressed with the intention of encouraging discussion. The risks associated with non-regulated PrEP use strengthens the call for the establishment of national programmes. There is a choice of PrEP medicines available that can help to reduce costs along with pointers towards best service delivery practice that can be taken from existing PrEP programmes.
S15
Cost effectiveness of PrEP in Europe
Brooke Nichols Johannesburg, South Africa Over the last two years, mathematical models and economic evaluations have demonstrated the cost-effectiveness of PrEP use in several countries across Europe, particularly for men who have sex with men (MSM) and injection drug users (IDUs). Key determinants of the cost-effectiveness of PrEP are 1) its selective use: prioritization to those people at highest risk of HIV, and 2) the cost of PrEP. In cases where the cost of PrEP was strongly reduced, PrEP was even shown to be cost-saving or, in other words, costs less to prevent one HIV infection than the lifetime healthcare costs of that infection. This body of work has contributed, in part, to the approval and financial reimbursement of PrEP in several countries and will continue to aid decision makers across Europe in deciding whether to provide and reimburse PrEP. Introduction: In 2013, a new reassortant avian influenza A H7N9 virus emerged in China. PCR-free detection methods have presently attracted tremendous attention because they exhibit rapid and highly sensitive detection of clinically relevant viruses. We therefore propose a simple strategy for rapidly and sensitively detecting the H7N9 virus using an intensity-modulated surface plasmon resonance (IM-SPR) biosensor. Materials and methods: A novel monoclonal antibody (mAb) was generated via immunization of trimeric recombinant hemagglutinin of A/Shanghai/02/2013(H7N9) strain. H7N9 vaccine strain was produced using reverse-genetics. IM-SPR biosensor was biult up with the bare Ag/Au (35/10 nm) chips captured with H7-mAb, the relatively inexpensive devices, a current-modulated diode laser and a data acquisition (DAQ) and integrated with fast Fourier transform (FFT) analysis.
Results:
The novel antibody exhibits significant specificity to recognize H7N9 virus compared with other clinical human influenza isolates (p<0.01). Experimentally, the detection limit of the proposed approach for H7N9 virus detection is estimated to be 144 copies/mL, which is a 20-fold increase in sensitivity compared with homemade target-captured ELISA using the identical antibody. For the measurement of mimic clinical specimens containing the H7N9 virus mixed with nasal mucosa from flu-like syndrome patients, the detection limit is calculated to be 402 copies/mL, which is better than conventional influenza detection assays; quantitative reverse transcription polymerase chain reaction (qRT-PCR) and rapid influenza diagnostic test (RIDT). Most importantly, the assay time took less than 10 minutes. (Picture 1)
Conclusions: Combined, the results of this study indicate that the proposed simple strategy demonstrates high sensitivity and time-saving in H7N9 virus detection and this assay has the potential to be used in applications and development of other emerging or re-emerging microbe detection platforms.
O2
Risk factors for multidrug-resistant tuberculosis patients in Casablanca-Settat, Morocco, 2012 -2016 Soad Redwane Ministry, Casablanca, Morocco Introduction: Multidrug resistance tuberculosis (MDR-TB) is defined as resistance to isoniazid and rifampicin. In Morocco, the prevalence of MDR-TB is 1 % in new cases and around 8.7% in among the restatement cases. The aim of this study was to identify the risk factors for MDR-TB, in Casablanca-Settat region, Morocco. Materials and methods: This was a case control (1 cases: 2 controls) study design. That have included patients notified as between January 1, 2012 and December 31, 2016 at the Center for the diagnosis of tuberculosis in the region. The cases are patients with pulmonary MDR-TB and the controls are patients with drug-sensitive tuberculosis treated, during the same period in the same center of care as the cases and declared cured at the end of treatment. In which the following factors were analyzed: socio-demographic and clinical characteristics, and MDR-TB patient contact. Data from MDR-TB cases and controls were analyzed using logistic regression model to identify risk factors of MDR-TB. For each factor, the association between the variables studied and MDR-TB was estimated by odds ratio (OR) with the 95% confidence interval. The analysis was performed using SPSS software version 24.0. Results: One hundred sixty-eight cases and 336 controls were collected. A male predominance was noted in the two groups, the mean age was 37 years for the cases and 35 years for the controls. Multivariate analysis revealed that cases compared to controls were significantly more likely to have had a previous history of retreatment (OR=60.9) or relapse after antituberculosis treatment (OR=20.6) or a patient -contact with MDR-TB (OR=10.5) or a hookah smoker (OR=3.6) or have a low monthly income. Conclusions: Our results emphasize that previous history of retreatment with first-line anti-tuberculosis drugs is the main risk factor regained, hence the interest of surveillance close and especially the application of the directly observed treatment, Short-Course (DOTS) strategy.
O3
Prevalence and incidence of hepatitis delta in patients with chronic hepatitis B in Spain Introduction: Hepatitis delta virus (HDV) infection causes the most aggressive form of chronic viral hepatitis. Given the defective nature of HDV, two major forms of acquiring hepatitis delta exist, one as HDV superinfection of hepatitis B chronic carriers and another as acute dual HBV and HDV coinfection. Most chronic hepatitis delta patients belong to the first category. In Western Europe, HDV spread during the 80s and 90s among injection drug users. Since then, new diagnoses of hepatitis delta have been rare and mostly recognized in immigrants from endemic countries. Materials and methods: The incidence of HDV superinfection was examined in a large cohort of HBsAg+ patients established since year 2000 at a large tertiary outclinic in Northwestern Spain. Anti-HDV antibodies were tested every 5 years. Results: During the study period, a total of 320 individuals were diagnosed as HBsAg. Overall, 68.4% were male; median 46-years old; 83.7% were native Spaniards; 7.8% were coinfected with HIV; and 6.3% were reactive for HCV-antibodies. The most frequent HBV genotypes in HBV-DNA viremic patients were D (71.3%) and A (15.3%). HBeAg+ was present in 21.9%. Overall, tenofovir was prescribed to 36.3% of HBsAg+ patients and 45.9% had undetectable HBV-DNA at last control. Ten patients (3.1%) had anti-HDV-Ab at first diagnosis. There were no further seroconversions for anti-HDV-Ab subsequently during a median follow-up of 11 years. Most anti-HDV+ patients were male, native Spaniards and were coinfected with HIV and HCV-Ab+. Interestingly, 2/3 women with delta hepatitis were foreigners, denied injection drug use, were younger than 40 years-old, and were negative for HCV and HIV. Introduction: Hepatitis A virus (HAV) infection remains a health risk for many HIV-infected patients, especially men who have sex with men (MSM), due to increased rates of unprotected intercourse and unsafe sexual behavior. Thus, vaccination is recommended for all HIV-infected patients without anti-HAV antibodies. Besides, evaluation of response to immunization is also recommended. Despite recommendations, adherence to the immunization remains low.
Materials and methods:
The present study is a retrospective review of HIV-infected patients followed-up at the Infectious Disease Unit of AHEPA University Hospital during 2005-2015. The study included 1,210 patients who underwent anti-HAV serology test. Adherence to immunization and seroconversion were also evaluated. Results: The mean duration of HIV infection was 5.1 years. Among the total study population, 338 had IgG anti-HAV antibodies from a previous infection and 20 did not undergo measurement of anti-HAV antibodies. According to anti-HAV titers, 852 patients were eligible for immunization, but only 627 (73.6%) completed the vaccination schedule (two doses), while 203 patients were partially immunized (one dose). The lack of social insurance was an independent risk factor for non-compliance to vaccine (p<0.0005). Moreover, low educational status was also associated with poor compliance (p<0.0005). In multivariate logistic regression analysis, ethnicity (p=0.027) and CD4 T cell count (p<0.001) were independent predictors of adherence. After vaccination (two doses), 506 patients (81%) had adequate antibody response (>20IU/L), whereas 121 (19%) patients did not. Seroprotection was not affected by age, sex, HIV risk factor, disease stage, HAART, nadir or current CD4 cell count and viral load. Conclusions: Vaccination against HAV was incomplete in HIV-infected patients. Low educational status and lack of social insurance contributed to poor adherence to vaccination, leading to suboptimal protection. Even after immunization, some patients still remain at high risk of HAV infection.
O5
Incidence and clinical characteristics of acute hepatitis A in a tertiary referral hospital in Madrid (2008 Madrid ( -2017 Introduction: The aim of this study was to investigate the clinical characteristics and changes in incidence of acute hepatitis A in our center during a recent outbreak in Madrid. Materials and methods: Data of patients diagnosed with acute hepatitis A from 2008 to 2017 were collected from our hospital (which covers an area of 450,000 inhabitants) retrospectively. Their demographic and serological characteristics, and clinical outcomes were analyzed. Results: A total of 132 patients (67% male, 86% Spanish) were included, with a median age of 37 years old. Incidence varies from 1.78 cases per 100,000 person-year in 2008 to 11.3 in 2017 (P<0,00001) (figure 1). 38.7% of total diagnosis referred to acute infections during 2017. 17% recognized risk factors for acquiring hepatitis A virus, of whom 41% remembered sexual risk patterns. 11.4% MSM, but there was no registry about sexual orientation in clinical records in 84% of study population. 2,8% were HIV-positive men on ART with suppressed viral load, and 7% suffered from diabetes mellitus. 5% had been previously vaccinated against hepatitis A virus (HAV). 38% were admitted to Hospital, without differences by sex, nationality, HIV status, or vaccination. The mean of the highest ALT level was 2,582 IU/L, AST 1785, total bilirubin 7.3 mg/Dl, ALP 286, GGT 313, and prothrombin activity 72%. Bilirubin reached highest levels 8 days after symptoms appeared (IQR 6-11). We observed co-infection with HAV in 13 patients: HBsAg was positive in 3%, 1.5% treponema RPR, 1.5% HPV, 0.75% anti-HCV, 0.75% EBV, and 0.75% HIV. 2.3% required ICU admission, 1.7% liver transplantation, and 1 patient died. The median duration of admission was 4 days (IQR 3-10). Median time for clinical resolution was 18 days, 22 days for hyperbilirubinemia, and 3 days for prothrombin activity.
Conclusions: Outbreak of acute hepatitis A virus infection was observed in 2017 with an increase of 6-fold in previous incidence. Hyperbilirubinemia should not delay discharge.
O6
Chemsex on PrEP: risk behaviours and STI incidence among PrEP patients using illicit substances Zoë Greenwald, Mariève Beauchemin, Danièle Longpré, Khadija Benomar, Stéphane Lavoie, Réjean Thomas L'Actuel Medical Clinic, Montreal, Canada Introduction: The growing practice of drug use during sex, known as chemsex, raises concerns that intoxication may lead to greater STI/HIV risk. Consequently, Pre-Exposure Prophylaxis (PrEP) is recommended for individuals engaging in chemsex. We aim to investigate associations between chemsex, risk behaviours and STI incidence among PrEP users. Materials and methods: This retrospective study of the l'Actuel PrEP cohort includes men who have sex with men, ages≥18, who consulted for PrEP from 2011-2017. Baseline behavioural risk characteristics reflect activities during the year prior to PrEP including: number of partners and condom use. Among individuals with ≥12 months follow-up, the cumulative incidence of STIs (Chlamydia or Gonorrhea) and relative risk (RR) over 12 months after PrEP initiation were compared between chemsex and non-chemsex users. Results: Among 1,881 patients who consulted for PrEP, 550 (29%) reported chemsex, 463 (25%) used marijuana and/or poppers, 332 (18%) reported alcohol consumption only, 536 (29%) reported no substance use. Individuals reporting chemsex used: GHB/GBL (n=310), Ecstasy (n=307), Cocaine (n=254), Cristal Meth (n=129) and Ketamine (n=102). The chemsex group exhibited increased risks when compared with non-chemsex group including more sexual partners (mean 34 vs 18, p<0.01) and a greater proportion reporting condomless insertive (62% vs 45%, p<0.01) or receptive anal sex (38% vs 27%, p<0.01). Chemsex users experienced higher 12-month cumulative STI risk (41% vs 32%), translating to a 48% increased STI risk (RR=1.48, 95%CI: 1.20-1.82).
Conclusions: This study demonstrates how PrEP reaches an already at-risk population with high levels of baseline drug consumption, which may contribute to increased STI risk on PrEP. Continued risk reduction counseling and combined prevention measures are needed to minimize potential harms associated with chemsex. Training for primary careproviders to increase awareness of chemsex risks is essential.
O7
HIV-1 sequences with more predicted glycans in acute infection were associated with the development of higher neutralization breadth Materials and methods: We examined 1,528 Env sequences (sampled at 1 week, 1 month and 6 months post-diagnosis) and neutralization data from 74 participants from Thailand and East Africa. Neutralization breadth was evaluated 2-3 years post-infection using a panel of 35 viruses: 16 broad neutralizers neutralized >70% of the panel while 12 non-broad neutralizers neutralized <35%.
Results: Sequences at 6 months after diagnosis (n=40) showed that the number of PNGS in Env did not change over time (p=0.91). Participants were infected with CRF01_AE viruses in Thailand or subtype A1, C and A1/C/D recombinants in East Africa but neutralization breadth did not differ by subtype (p≥ 0.25). Considering all time points, the mean number of PNGS was not significantly different between broad (29.2) and non-broad (27.8) neutralizers (p=0.11). Yet, there was a significant positive correlation between the mean number of PNGS and the neutralization breadth measured 2 years post-infection (r=0.64, p<0.01 with acute Env). When looking at the number of PNGS in the five variable loops of Env, this signal appeared mostly driven by PNGS in V4: r=0.41, p=0.05. Conclusions: Similar to reports showing that glycan holes negatively affect the development of neutralization breadth, we found that Env with less PNGS led to narrower neutralization. These results highlight that PNGS counts in acute infection inversely associate with the neutralization breadth 2 years post-infection. Better characterizing the role of specific glycans is needed to clarify the relationship between the glycan shield and the development of a broadly-neutralizing response.
O8
Frequent CXCR4-tropism in newly diagnosed individuals from an HIV-1 F1 subtype cluster rapidly expanding among men who have sex in men in Spain Introduction: An HIV-1 F1 subtype cluster has recently expanded among men who have sex in men (MSM) in Spain, mostly in the Northwestern region of Galicia. This cluster is associated with higher viral loads, lower CD4+ cell counts at diagnosis, delayed virological response and poorer CD4+ cell recovery after initiation of antiretroviral (ARV) therapy. Here we examine coreceptor usage in viruses from the F1 cluster from newly diagnosed individuals. Materials and methods: An HIV-1 envelope segment of 366 nt in the V3 region was amplified from RNA extracted from plasma from recently diagnosed (<1 year) individuals residing in 6 regions of Spain and sequenced. Coreceptor usage was predicted with Geno2pheno, using a false positive rate (FPR) cut-off of 10%. Maximum likelihood phylogenetic trees were constructed with PhyML, using the GTR+G+I evolutionary model, with assessment of node support by the approximate likelihood ratio (aLRT) test, using a ShimodairaHasegawa(SH)-like procedure. Nodes with ≥0.9 SH-like aLRT values were considered well supported. Results: 62 viruses branched within the previously identified F1 cluster. 27 (43.5%) of them were predicted to be X4 or mixed/dualtropic with Geno2pheno (using a 10% FPR cut-off), with 19 of these viruses belonging to a subcluster. Within this subcluster, all 15 viruses that did not branch within a subsubcluster (which comprised mostly CCR5-tropic viruses) were CXCR4-tropic. Conclusions: Viruses from newly diagnosed individuals from an HIV-1 F1 subtype cluster rapidly expanding among MSM in Spain are frequently predicted to be CXCR4-tropic, with most CXCR4-tropicviruses branching within a subcluster. Further studies will be needed to determine whether CXCR4-tropism is associated with the poorer virological and immunological responses to ARV therapy reported for this cluster. Jean-Pierre Routy levels with markers of gut damage and immune activation in acute (AHI) and chronic (CHI) HIV-infected patients on long-term ART. Materials and methods: 134 participants without suspicion of fungal/bacterial infection and/or colitis were assessed in a crosssectional analysis, including 74 AHI, 39 CHI patients and 21 uninfected controls. A subgroup of 32 AHI participants was prospectively assessed. Plasma βDG levels were quantified using Fungitell® assay and were compared with age, sex, viral load, CD4 count, CD4/CD8 ratio, markers of gut damage (I-FABP), microbial translocation (LPS, LBP and sCD14) and inflammation (IL1-β, IL-6, IL-8 and TNF-α). Results: Plasma βDG levels were elevated during AHI (59.4±33.6 pg/mL, p=0.041) and CHI (135.6±48.6 pg/mL, p<0.001) versus controls (30.6±10.8 pg/mL). A significant negative correlation of βDG was only observed with CD4 count (r=-0.334; p=0.001). A significant positive correlation of βDG was observed with current viral load (r=0.429; p<0.001) in untreated group and with LBP (r=0.413; p=0.007), sCD14 (r=0.338; p=0.001), IL-6 (r=0.334; p=0.001) and p<0.001) in HIV-infected patients. βDG levels increased over 2-years in the untreated AHI (111.2±96.4 pg/mL p<0.001) and remained stable for those who initiated early treatment. CHI patients on 12±4 years of ART had the highest βDG levels (191.9±49.8 pg/mL, p<0.001). Conclusion: Elevated plasma βDG levels correlated with the validated markers of gut damage, microbial translocation and immune activation. Plasma βDG levels did not decrease over time with ART and may directly contribute to maintenance of innate immune system activation.
O9
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Two diseases, same person: moving towards a combined HIV and TB continuum of care , IQR: 41-425) and were divided into 4 subgroups. We characterized the DNA and RNA enteric virome using shotgun next-generation sequencing. Viral sequences were identified using SURPI computational pipeline. Results: We identified a variety of viral sequences assigned to plant viruses, phages and human viruses. We also detected Cryptosporidium virus in 2 samples from HIV+ individuals with CD4<50, demonstrating infections with the protozoan parasite Cryptosporidium. Human virus sequences were assigned to commensals and pathogens belonging to different families including Anelloviridae, Papillomaviridae, Caliciviridae, Picornaviridae, and Adenoviridae (Figure 1 ). Our data showed a marked expansion of human viruses in HIV+ subjects with CD4<50 and 50≤CD4<200 compared to HIV− subjects (p=0.0001 and p=0.0033, respectively). In particular, low CD4 T cell counts were associated with a striking increase in sequences from the Anelloviridae family (p<0.0001), commensal viruses suggested to reflect the overall state of immunosuppression. Importantly, 20 near full-length viral genomes were obtained, allowing phylogenetic analyzes of identified strains. Conclusions: Our data demonstrate an increase in sequences from human enteric viruses including commensals and pathogens in advanced HIV infection. This viral expansion is a reflection of HIV-associated immunodeficiency and might contribute to GI tract damage and persistent inflammation. Moreover, cell-cell dissemination has been suggested to be more potent and difficult to neutralize than cell-free virus. The development of efficacious preventive strategies will greatly benefit from the knowledge about capability of broad neutralizing antibodies (bNAbs) to protect against cell-cell transmission. Materials and methods: We developed a cell-to-cell transmission assay and assessed neutralization function of bNAbs using TZM-bl and human PBMC as target cells and in vivo SHIV162P3-infected splenocytes as donor cells. We compared the efficacy of 1 st generation bNAbs (b12, 2G12, 2F5 and 4E10) and 2 nd generation bNAbs (3BNC117, N6, 10-1074, PGT128, PG16, PGDM1400, 10E8 and PGT151) combinations against both cell-free and cell-cell transmission. Results: When using first generation bNAbs, the triple combination of 2F5+2G12+4E10 was more effective to inhibit both cell-free and cell-cell transmission compared to the double combinations and to the single antibodies. 2F5 and 4E10 suppressed cell-free infection, but when cell-cell infection occurred, only 2F5 could prevent transmission to PBMCs. Among the second generation bNAbs used, 10-1074, PGT128, PGT151 and N6 were the most potent to block the two infection modes, with 2 log lower IC50 values compared to first generation bNAbs. Moreover, a double combination of Abs could inhibit cell-cell transmission as well as the triple combination, being the association of 10-1074+PGT151 the most effective (IC50 0.26±0.06) among the combinations of 2 Abs used. Conclusions: Our results demonstrate that cell-cell SHIV162P3 transmission is less sensitive to bNAbs compared to cell-free SHIV162P3 and that a combination of bNAbs may more efficiently prevent cell-cell transmission. The number of people with HIV (PLWH) ≥50 years is on the rise. Although it is known that older age is associated with lower risk of viral rebound on ART, it is less clear whether this continues after the age of 50. Further, immune function in the HIV-negative population is known to decline in older age, but it is unknown if this is mirrored in PLWH with normalized CD4 count. Materials and methods: PLWH attending a single HIV center were followed from the first date on or after 1/1/2005 with VL<50 cps/ml on ART until viral rebound (2 consecutive VL>200cps/ml) or last follow-up. Multiple viral suppression (VS) episodes per person were included. Rates of viral rebound were adjusted for potential confounders using Poisson regression with GEEs. For immune analyzes, people were followed from the first time they were aged≥50 yrs, VL<50 cps/ml on ART with CD4>500cells/μl, until date of viral rebound or last follow-up. CD4 count & CD4/CD8 ratio change over this time was calculated using multi-level linear regression. Results: 4,045 people were followed for median (range) 6.3 (0.0-11.4) person-years and 1 (1-5) VS episodes. Viral rebound rates among >50 yrs were substantially lower than <40yrs and continued to decline with increasing age (Table 1) . 1,118 people included in immune analyzes had median (range) follow-up of 3.9 (0.0-11.4) years. An increase in CD4 count of +12 cells/μl (95% CI +9,+15;p<.001) per year older and in CD4/CD8 ratio of +0.031 (+0.028,+0.035;p<.001) was observed. Conclusions: Despite increasing prevalence of co-morbidities, rates of viral rebound continue to decline with increasing age. Further, this is one of the first studies showing CD4 T-cell preservation in those aged ≥50 years and stable on ART. These positive results need to be confirmed in other PLWH cohorts.
O16
Environmental and occupational exposures as predictors of airflow obstruction in an HIV tertiary care clinic
Cecilia Costiniuk
Introduction: Studies have reported an increased prevalence of Chronic Obstructive Pulmonary Disease (COPD) in people living with HIV(PLWH) compared to HIV-uninfected controls. We aimed to determine whether occupational and environmental exposures were associated with the prevalence of COPD in unselected PLWH using spirometry to guide screening strategies for COPD. Materials and methods: All persons ≥18 years of age followed at the Chronic Viral Illness Service in Montreal, Canada with HIV were invited to participate, regardless of smoking status or history of known COPD/asthma. Individuals underwent standard spirometric testing both pre and post salbutamol bronchodilator and completed questionnaires on smoking, occupational and environmental exposures. The presence of COPD was determined and multivariate logistic regression was used to evaluate the association between occupational and environmental exposures and COPD. Results: There were 508 participants. Median age (Q1;Q3) was 51 (44;58), and 29% were female. Participants were on antiretrovirals for a median duration of 10 (6;17) years with 92% virally suppressed. Median CD4 count was 599 (440;786). Percentage of current, former and never smokers was 23%, 29% and 48%, respectively. Prevalence of COPD as defined by spirometry was 11%. Composite occupational exposures (≥3 months) and environmental exposure (≥6 months) were experienced by 23% and 34% of participants, respectively. The following risk factors for COPD were assessed: smoking history Introduction: Whilst reporting improved renal and bone safety profiles, studies have noted changes in lipid profiles among people living with HIV (PLWH) switching away from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF). This study aimed to characterise changes in lipids observed after switching to TAFcontaining antiretroviral therapy(ART) in a real-world setting. Materials and methods: We analyzed lipid values from PLWH enrolled in the UCD ID Cohort study who switched to TAF-containing ART from January 2016 to July 2017. Routine laboratory data, ART history and use of lipid lowering therapy (LLT) were analyzed. Lipids were stratified using NCEP-ATPIII 2016 criteria to assess severity of dyslipidaemia. Logistic regression analyzes were performed to identify factors associated with worsening dyslipidaemia. Results: Of 775 PLWH enrolled in the cohort, 238 switched to TAF, 194 had both baseline and follow-up lipids measured a median 168 (100-286) days post-switch. Of the 194 analyzed, age was 46 (39-53), duration of known HIV was 10 (4.25-15) years. 70.6% were male and 69.1% Caucasian. Most common ART backbones pre-switch were TDF (85.1%) and abacavir (11.3%) with 23.7% on LLT at baseline and 4 (2.1%) commencing LLT post switch. Although total cholesterol (TC), LDL and HDL significantly increased (+0.3(-0.2-0.9) mmol/l, p<0.0001; +0.2(-0.1-0.7) mmol/l, p<0.001; +0.065 (-0.09-0.19) mmol/l, p=0.003), TC:HDL ratio did not significantly change. When stratified (Figure 1 ), there were significant increases in the proportions of PLWH with more severe dyslipidaemia for TC and LDL (p<0.0001 and p=0.005). In logistic regression, use of LLT at baseline significantly attenuated the risk of worsening TC (0.23(0.053-1.035), p=0.06) or LDL (0.23(0.079-0.688) p=0.01) levels post-switch. Conclusions: Although lipid profiles worsened post switch to TAF, use of LLT pre-switch attenuated the risk of worsening lipids. How these changes will impact on cardiovascular risk in PLWH remains to be determined.
O18
Understanding characteristics of daily and ondemand PrEP prescriptions Zoë Greenwald, Mariève Beauchemin, Louise Charest, Stéphane Lavoie, Alexandra Hamel, Danièle Longpré, Réjean Thomas L'Actuel Medical Clinic, Montreal, Canada
Introduction: Pre-exposure prophylaxis (PrEP) may be prescribed in daily or intermittent 'on-demand' regimens, taken before and after sex. Decisions for which regimen will be most suitable for an individual seeking PrEP result from discussions between PrEP candidates and their clinicians. We aim to investigate trends in PrEP prescriptions related to patient characteristics, clinicians and calendar year.
Materials and methods:
We analyze data from the l'Actuel PrEP Cohort from March 2015 to December 2017. Patient variables include age, education, revenue, number of sexual partners within 12 months, and drug use during sex. Clinicians were stratified by years in practice (<10 vs ≥10 years). Predictors of prescription are summarized by univariate and multivariate logistic regression. Results: Among 1,556 MSM prescribed PrEP at baseline, 1217 received daily (78.2%) and 339 received on-demand (21.8%) baseline regimens. When compared to patients receiving daily prescriptions, those receiving on-demand PrEP prescriptions at baseline were on average older (39.3 vs 36.2 years, p<0.01). 32 clinicians prescribed PrEP; those with ≥10 years in practice prescribed on-demand PrEP more often than those with <10 years in practice (23.4% vs 18.2%, p=0.02). On-demand prescriptions were associated with older age, fewer sexual partners, lower likelihood of having a seropositive partner and greater likelihood of having a clinician with ≥10 years in practice (Table 1) . No association was observed for education or revenue in the adjusted model. No changes in on-demand prescription rates since 2015 were observed. Conclusions: Decisions for PrEP regimens should continue to be based off discussions between patients and providers to select the regimen which best fits each individual's needs and should be adaptable over time. Offering a diversity of dosing strategies is essential to ensure individuals find combined prevention strategies that adapt to their lifestyle.
O19
High seroconversion rates following PrEP discontinuance in a Montreal clinic Zoë Greenwald, Mariève Beauchemin, Khadija Benomar, Gabrielle Landry, Alexandra Hamel, Michel Boissonnault, Louise Charest, Danièle Longpré, Stéphane Lavoie, Réjean Thomas L'Actuel Medical Clinic, Montreal, Canada Introduction: Variations in individual PrEP use have been described by the seasons of risk theory; whereby patients may start and stop PrEP episodically. However, measures of rates of episodic PrEP use, reasons for PrEP discontinuation and rates of seroconversion following PrEP stops are scarce. Materials and methods: We aim to measure rates of temporary and permanent PrEP discontinuations, describe stop reasons and measure seroconversion rates subsequent to stops using the l'Actuel PrEP cohort. We included patients who had initiated PrEP and returned for ≥1 follow-up visit prior to September 2017 (N=1258). Person-time at risk was calculated from stop date to date of seroconversion or censored at last negative HIV test among patients maintained in care. Results: Our PrEP cohort measured 450 consistent users (36%), 114 users (9%) who temporarily stopped and re-initiated PrEP, 214 individuals who permanently discontinued (17%) and 480 individuals who have been lost to follow-up for ≥6 months (38%). HIV incidence following discontinuation was 3.9 cases per 100 PY. Among individuals who discontinued PrEP, the most commonly reported stop reasons were side effects (14%), financial reasons (9%), individual preference (7%), and changes in sexlife, such as entry into a stable relationship with seronegative partner (13%), entry into relationship with seropositive undetectable partner (4%), break-up with seropositive partner (4%) or sexual abstinence (10%). Conclusions: For some, PrEP use may be a transient rather than constant HIV prevention method. The high rates of seroconversion following PrEP discontinuance indicate the need for clinical support based on contextual lifestyle factors that may lead individuals to stop PrEP, while remaining at high risk for HIV infection. Increased risk counseling and resources to reduce loss to follow-up for PrEP users are essential. Support of PrEP and combined prevention measures remain key to ending the epidemic by 2030. Material and methods: In-depth interviews and focus group discussions were applied to identify 1) attitudes, motivations and needs of sex partners of PWIDs, 2) Barriers and support factors for involvement in HIV prevention programs 3) services needed for sex partners. The convenience sampling was used to recruit PWIDs, sex partners and service providers. Study was provided in 5 cities of Georgia. Results: The following barriers were revealed for sex partners of PWIDs: fear of HIV testing and associated stigma; low awareness of HIV transmission risks and the importance of testing; low awareness about anonymous free HIV testing services; feeling of shame to do HIV testing, especially in small cities; lack of women-oriented services at harm reduction sites; negative approach towards PWIDs from society and criminalization of drug consumption in the country. The needed services for sex partners of PWIDs are free HIV and HCV testing; medical consultations and referral to treatment HIV, HCV, Syphilis, TB, reproductive healthcare reatment programs. Conclusions: More efforts are needed to address the barriers that were revealed by this study. Harm reduction program personnel should increase of motivation of sex partners of PWIDs to do testing on HIV and other infections; Risk counseling and working with couples should be enhanced for decreasing HIV associated risks and better utilization of harm reduction services; Besides, women-oriented services should be developed and adjusted to the needs of sex partners of PWIDs. In sub-Saharan Africa (SSA), epidemic control requires increased HIV testing and treatment for adolescents and young adults (15-24 years). For 21 highest burden countries in SSA (95% regional HIV burden), we reviewed the published national HIV care continua for this population and compared the progress towards 90-90-90 with other age groups.
Materials and methods:
For the 21 countries, we searched PubMed, US President's Emergency Plan for AIDS Relief (PEPFAR) operational plans, country progress reports and conference abstracts for the latest age-specific continua.
Results: Of the 21 countries, age-specific continua, published between 2012-2017, were available for only 10 countries (53% regional burden). The age distributions were <15,15-24 and >25 years. All countries reported data on second 90 (on ART) while three countries on first 90 (diagnosed) and eight countries on third 90 (viral suppression). ART coverage among 15-24-year old living with HIV varied from 17%-72% and was significantly lower than the ART coverage for <15 and >25-year-old in all but three countries (Uganda, Cote d'Ivoire and Cameroon). Viral suppression among 15-24-year olds varied from 10%-58% and were lower than the national average in all countries except one (Figure 1 ). Botswana has achieved 90-90-90 for all age groups except 15-24-year-old. In Namibia, ART coverage and viral suppression among all PLHIV were 49 and 46 percentage points higher than that among 15-24-year old, respectively. Achieving 90-90-90 requires achieving 90-90-90 for 15-24-year olds.
Conclusions: Comprehensive published HIV care continua for adolescents and young adults are limited and there exist some inconsistency in the data, calling for improved M&E for reliable data. The results are similar to PEPFAR Population-based HIV Impact Assessments. There is also a need for improved HIV efforts for the bulging youth population in SSA while sustaining the progress made towards 90-90-90 for paediatrics and adults.
DP3
Analysis of quality-adjusted life years (QALYs) in HIVpositive and HIV-negative subjects enrolled to the UPBEAT (Understanding the Pathology of Bone Disease in HIV Infected Subjects) cohort University of Cambridge, UK Introduction: The QALY is a generic measure of disease burden that captures both the quality (QoL) and quantity of life lived. We aimed to compare QALYs between HIV-positive (HIV+) and HIV-negative (HIV-) subjects. Materials and methods: Cross-sectional analysis of QALY in HIV+ and HIV− subjects enrolled in the HIV UPBEAT cohort. QALYs were calculated using the SF-6D, which is derived from the SF-36 Health survey, as a measure of health utility, multiplied by the expected remaining lifespan. Data on life expectancy was obtained from the national statistics office (http://www.cso.ie): 78.4 years for men and 82.8 years for women. SF-6D and QALY data are mean (SD). Between group differences were assessed using Mann-Whitney/Student's t-test and Chi-square tests. Impact of HIV status on QALY was assessed using multivariable linear regression. Results: A total of 244 (106 HIV+, 138 HIV-) subjects were included in the analysis. The HIV+ group was younger, more likely male and of African origin. Demographic and socio-economic differences are shown in Table 1 . All HIV+ were on antiretroviral therapy (ART), 98% had undetectable HIV-RNA, median CD4+ (IQR) count was 662 (513, 851) cells/mm 3 and median time since HIV diagnosis was 11.0 (9.0, 14.0) years. Despite lower SF-6D in HIV+ (0.75 (0.10) vs HIV− (0.82 (0.08), p=0.001), the calculated unadjusted QALYs were similar between the two groups (24.4 (7.6) vs 24.6 (8.34)). However, after correcting for differences in age, HIV+ status was independently associated with a mean reduction of 2.8 QALYs (95% Confidence Interval −3.7, −1.8, p<0.0001). Further adjustment for other demographic and socio-economic parameters minimally impacted on the observed association (−2.0 (−3.0, −1.0), p<0.0001) Conclusions: In our cohort, HIV+ subjects on effective ART reported lower health quality compared to HIV− individuals. HIV+ status was associated with a loss of 2 QALYs after controlling for age and other potential socio-demographic confounders. Introduction: HIV transcription frequently persists intracellularly in virologically suppressed patients. We sought to evaluate HIV persistent transcription (HIVpt) in patients on stable first line regimens. Materials and methods: Virologically suppressed patients for one year on first-line treatment with EFV or ATV combined with emtricitabine and tenofovir were eligible for this study and followed up for one year. Simultaneous ultrasensitive subpopulation staining/ hybridization in situ (SUSHI) was performed to identify HIVpt in CD4+ and CD4+CD45RO+ T-cells. Factors associated with HIVpt were evaluated with logistic regression models. Results: In the CD4+ T-cell population, HIVpt affected 23 out of 51 patients, whereas in the CD4+CD45RO+ T-cell population, HIVpt was present in 29 out of 51. HIVpt in the CD4+CD45RO+ T-cell population may be associated with ATV treatment (OR 2.86, 95% CI 0.87-9.37, p=0.083). No association of HIVpt status with loss of virological suppression or CD4 evolution was observed. Conclusions: The HIVpt profile may differ across different cell populations and antiretroviral regimens. Further studies are required to define the clinical significance of this finding.
DP4
DP5
Clinical resistance to dolutegravir assessed by next generation sequencing in pre-exposed raltegravir patients of subjects who are prescribed chemoprophylaxis against malaria do not follow it properly, furthermore it is not even started among most of these subjects.
DP7
Universal HTLV screening in transfusion centers unveals significant misdiagnosis of HLTV-1 infection in Spain Since then, 247 cases (70%) of total HTLV-1 cases have been identified, being 104 (44%) first time blood donors. All of this subset of patients was asymptomatic whereas 57 out of 138 cases identified at hospitals presented with clinical symptoms (23 HAM/TSP, 19 ATLL and 15 with other HTLV-associated conditions). In addition, 5 cases acquired HTLV-1 infection after received solid organ transplants from 2 HTLV-1+ donors (4 kidneys and 1 liver). Interestingly, all but one developed HAM/TSP shortly within the first year of surgery. Conclusions: HTLV-1 misdiagnosis must be common in Spain, based on the ratio of symptomatic/asymptomatic carriers at the national registry. Given that immigrants from HTLV-1 endemic regions currently represent 10% of the 47 million country population, universal HTLV screening of first-time blood donors and solid organ transplant donors and recipients (to prevent transmission and disease) should be consider. It would be cost-effective, halting the spreading and clinical burden of HTLV-1 in Spain.
DP8
Active hepatitis C is associated with a larger HIV reservoir in successfully treated patients Introduction: HIV-chronically infected patients can retain an extremely low viral reservoir (LVR). Awareness of factors associated with a LVR could be useful for HIV eradication strategies. We analyzed the prevalence of LVR and potentially associated risk factors in a cohort of successfully treated HIV-patients Materials and methods: Successfully treated HIV-patients were identified among a cohort of randomly selected subjects. Background parameters, CD4 and CD8 cell count, HIV-RNA and HIV-DNA viral loads, hepatitis B and C serological status and viral loads, markers of immune activation and neuropsychological performance evaluated by a single trained neuropsychologist were collected. Active hepatitis C was defined by positive HCV antibodies and detectable viral load.
To identify potential parameters associated with LVR, patients were divided into two groups: those with LVR and those without LVR (wLVR), according to HIV-DNA values below or above 10 copies/ 106PBMC, respectively. Results: Among 265 patients included in the cohort, 95 had been successfully treated for at least 6 months (mean age 46, 71% male, 29% with AIDS, 40% HCV-coinfected, mean CD4 nadir: 232, mean CD4 cell count: 592, years of contamination: 14; years on cART: 9). Eleven patients had a LVR (11.6%). Active hepatitis C but not HCV-positive serology was the only risk factor for detectable HIV-DNA (0% in LVR, 32% in wLVR, p=0.03). Patients with HCV but inactive hepatitis had either received Peg-IFN and Ribavirin therapy or had spontaneously cleared HCV-RNA. Neither months on HCV treatment, time periods of HCV therapy nor neurocognitive performance differed between LVR and wLVR groups.
Conclusions: Approximately 10% of successfully treated subjects harbored LVR. Active hepatitis C appears to affect the size of the HIV reservoir. Strategies for HIV eradication should therefore consider the role of hepatitis C, while interaction mechanisms between the two viruses should be investigated. Results: A total of 359 HIV-2 persons had been recorded so far. Overall, 37 (10.3%) were HIV-D+ and are our study population. Male were 62.2%, 19 (51.3%) came from West Africa whereas 7 (18.9%) were native Spaniards. African countries of origin were: 8 GuineaBissau, 3 Equatorial Guinea, 3 Gambia, 2 Cameroon, 2 Liberia, 2 Senegal, 1 Ivory Coast, 1 Mali, 1 Ghana, 1 Mozambique, 1 Nigeria and 1 unspecified Sub-Saharan country. There was one Brazilian and one French native as well. The 75% of HIV-D+ persons harboured HIV-1 non-B subtypes. Co-infection with HBV (HBsAg+) was seen in 3 (8.1%). At diagnosis, 29.7% had AIDS-defining events. Median CD4 count was 145 cells/mm 3 and median plasma HIV-RNA was 4.51 log copies/mL for HIV-1 and 3.64 log copies/mL for HIV-2. Last recorded ARTs were based on: boosted-PI (14: 7 LPV/r, 6 DRV/r and 1 ATV/r), INSTI (6: 3 DTG and 3 RAL) and 1 with 3 NRTI (Trizivir). After beginning ART, undetectable viremia was achieved in 88.9% for HIV-1 and in 78.5% for HIV-2. Median CD4 counts risen up to 512 cells/mm 
DP11
Impact of HIV-associated immunodeficiency on the enteric bacterial microbiome Sandra Pinto Cardoso, Monserrat Chávez-Torres, Celia Boukadida, Daniela Garrido-Rodríguez, Amy Peralta-Prado, Gustavo Reyes-Terán Respiratory Disease National Institute, Infectious Diseases, Mexico City, Mexico Introduction: Alterations in the enteric microbiome have been reported in HIV infection (depletion in key commensals, reduced microbial diversity and expansion of the virome). We sought to understand the effects of HIV-associated immunodeficiency on the enteric bacteriome. Materials and methods: Stool samples were collected from 84 individuals ( Table 1 ). All HIV-infected individuals were naive to antiretroviral therapy. We used 16S rRNA sequencing and QIIME to describe and analyze the bacterial microbiome. Results: Bacterial diversity was reduced with HIV infection (p<0.001), with immunodeficiency (HIV− vs CD4<200, p=0.038) and antibiotic use (p<0.001). Unweighted Unifrac analysis followed by ANOSIM testing showed no clustering by HIV status (p=0.94), weak clustering by CD4 group (HIV− vs CD4<200 p=0.028 and CD4<200 vs CD4>200, p=0.002) and strong clustering by antibiotic use (p=0.001). Sixty-six operational Introduction: On January 2018, the World Health Organization (WHO) launched reviewed recommendations for rabies immunization, aiming at simplified regimens to make rabies protection more affordable worldwide. As new WHO statement accepts just two doses of rabies vaccine at days 0 and 7 in preexposure prophylaxis (PrEP), awareness of vaccinees about risks and medical interventions after an animal exposure has become maybe more important. Materials and methods: A prospective survey in travelers attending a Tropical and Travel Medicine unit located in Madrid was performed along 2017. All consecutive subjects that had received complete PrEP vaccination for rabies in the past were recruited; an anonymous questionnaire was designed to assess their awareness on rabies risks and the measures to take in case of animal attack. Results: A total of 100 travelers (mean age 34±11 years-old, 58% females) were interviewed. Rabies PrEP had been administered 5±5 years ago, before traveling to Asia in 43%, Africa in 39% and America in 18%. India (24%), Uganda (8%) and Ethiopia (7%) were the most common destinations when PrEP was indicated. Administration of PrEP was done most frequently in volunteers (50%) and tourists (41%). Most vaccines recognized dogs (97%) and monkeys (85%) as potential risk for rabies, but less frequently bats (73%) and cats (36%). Animal scratching was viewed as indication for postexposure prophylaxis (PEP) only in 59% of travelers. Awareness of recommendations after an animal attack was as follows: intense wound washing in 68%, antibiotic prophylaxis in 42% and need for PEP vaccine doses in 82%.
DISCUSSED POSTER PRESENTATIONS
Conclusions: Among travelers that have received rabies PrEP, cat and bat exposure and animal scratching are not frequently viewed as risks for rabies. Need for wound cleansing and antibiotic prophylaxis after animal attack are often overlooked by rabies vaccinees.
DP13
Are data-driven combined prevention services the key to ending the epidemic? Take-home messages from HIV cases diagnosed from 2008 to 2016 at l'Actuel Introduction: Colony-stimulating factor 1 (CSF1) regulates the proliferation, survival, and differentiation of macrophages (MPs) through the receptor tyrosine kinase CSF1R. Levels of CSF1 in the cerebrospinal fluid are elevated in HIV patients with cognitive impairment. However, little is known about the expression of its receptor CSF1R in the brain. Using the simian immunodeficiency virus (SIV)/macaque model of HIV infection, we investigated whether CSF1R is expressed on brain MPs and microglia (MG) in vivo and whether it is activated after lentivirus infection in vivo and contributes to development of encephalitic lesions.
Materials and methods:
We examined, using multi-label and semi-quantitative immunofluorescence microscopy, the protein expression level and cellular localization of CSF1R in cortical brain tissues from uninfected (n=3) and SIV-infected macaques with (SIVE, n=4) or without (SIVnoE, n=4) encephalitis. Results: In the uninfected brain, CSF1R protein was detected only in MG and brain MPs but not in other brain cell types. MG constitutively expressed CSF1R at low levels and its expression was largely unchanged in SIVnoE and SIVE animals. Brain MPs including perivascular macrophages (PVMs) expressed higher levels of CSF1R, compared to MG. We found significantly increased expression of CSF1R on the infected PVMs and lesional MPs in the brain of SIVE animals. Moreover, the per-cell expression of CSF1R determined by its mean pixel intensity (MPI) correlated positively with the MPI of SIV p27 in SIV-infected PVMs. Using phosphorylated CSF1R at tyrosine residue 723 as a marker for CSF1R activation, we found activation of CSF1R signaling in infected brain MPs. We also found colocalization of CSF1R and its ligand CSF1 in brain MPs in the brain of SIVE animals. Conclusions: These findings are useful for developing a selective approach targeting infected brain MPs, with brain-penetrant CSF1R inhibitors now available, for elimination of CNS MP reservoirs, while not affecting resting uninfected CSF1R low MG and PVMs.
DP15
Healthy moms and healthy infants: 12 years of successful mother-to-child HIV transmission prevention in a community health center in Bamako, Mali Initially, HIV+ mothers were referred to a city hospital for treatment and GAIA covered transportation expenses, but in 2008, MTCTP treatment was provided directly at the CSCOM. All HIV+ women were provided with ARVs according to local protocols and encouraged to give birth at the clinic, where delivery costs were covered, and infants Introduction: Sri Lanka lacks basic harm reduction needs for PWUD/PWID which make them prone to blood born viruses HIV, hepatitis B and C. Hence, this study was conducted aiming at understanding the pattern of drug use among non-institutionalized PWUD and PWID to recommend policies and programs in order to minimize harm to the PWUD/PWID in Sri Lanka. Material and methods: A cross-sectional study in six high drug use prevalence districts was conducted among 283 PWUD and 174 PWID, recruited through snow-ball sampling and data collected using a structured questionnaire. Moreover, 36 Key Informant interviews (KII) were conducted among PWUD/PWID, Treatment provider, Family member/Spouse/partner and Law enforcement personnel. Ethics clearance was obtained from faculty of medicine, University of Colombo. Results: Majority (95%) were males in late 30s, while heroin smoking initiated around 19-20 years, injecting starts around 28. 'Peer pressure' and 'curiosity' were reported reasons. 64% of PWID and 73% of PWUD had scores more than 26 on WHO ASSIST. 91% PWIDs reported injecting heroin. 83% of PWID injected 'daily' with 64% injecting '2-3 times/day'. 85% reported sharing 'ever', while 64% reported 'last one month' and 68% reported sharing in the first instance of injecting. 52% of PWID and 38% of PWUD reported unprotected sex with sex workers. More than 90% had been apprehended by police and majority (84% PWID and 78% PWUD) had been to jail. KII highlighted deep seated prejudices, widespread stigma and discrimination faced by PWUD/PWID and misconceptions regarding harm reduction. Conclusions: Triple burden of risk; PWUD are at risk of transition to injecting, and high prevalence of risky injecting and sexual practices identified. Criminal justice and poor access to addiction treatment with non-existence of harm -reduction interventions are seen. Legal and Policy reforms with services promoting civil society in the decision-making, advocacy for Opioid Substitution Treatment and harm-reduction interventions are important.
P5
Factors associated with deprivation according to the EPICES score in older HIV patients: results of the VISAGE French study Introduction: People living with HIV (PHIV) grow older and accumulate multiple health problems earlier than the non-infected. Moreover, as the burden of social inequalities in health is highlighted, the individual evaluation of social conditions with a composite, synthetic, easy to apply tool became an important challenge. Our study, conducted by the VISAGE group, a French multidisciplinary study group focusing on elderly PHIV, aimed to assess the prevalence of deprivation and his relationship with health indicators. Materials and methods: This 18-months multicenter cross-sectional study carried in 2014 had involved PHIV >=50 years, followed-up in HIV dedicated hospital medical units in France. Deprivation (ES
>=30.17) was measured with the EPICES score (Evaluation of Deprivation and Inequalities in Health Examination Centers, ES).
Besides classical HIV data, we collected: sex, age, body mass index, comorbidities, Fried five frailty markers, socioeconomic and behavior factors and geriatrics assessment. Results: 494 PHIV >=50 completed ES, means age 58.5 +/− 7.0 years, 72.9% men. Prevalence of deprivation was 49.0%. The main deprived item was the lack of social care (88.9%). Multivariate logistic analysis, comparing deprived (n=242) and non-deprived (n=252) PHIV, showed that alcohol and drug uses (OR: 4.07), risk of depression (OR: 3.59), chronicle pulmonary disease (OR: 3.10), hepatitis C (OR: 1.96), felt chronic pain (OR: 1.11) were significantly (p<.05) linked to deprivation. Conclusions: It would be crucial to measure deprivation more routinely with synthetic and validated tools during the follow-up of PHIV. Targeted comprehensive care procedures, involving social and psychological supports, need to be implemented urgently to reduce the burden of deprivation. Health professionals need to be attentive to the pain status of older PHIV and to those with chronic pulmonary diseases. They should refer deprived patients, especially those with alcohol misuse and mental distress, to specific supports in and out hospital. Introduction: Human immunodeficience virus (HIV) infection affects mostly young adults when they are most economically productive and often have a family charge. The socioeconomic impacts are very severe: reduced life expectancy reduced economic activity and increased charge on health systems. Our study aim was to improve knowledge, attitudes and practices regarding sexually transmitted diseases (STDs) and HIV. Material and methods: We conducted a cross-sectional study of knowledge, attitudes and behaviors using an anonymous selfadministered questionnaire of 5032 young recruits newly recruited soldiers in 2009 and 2010. Results: The participants of our study were predominantly male (96%) and 96% were single. More than 90% of the participants had knowledge of STDs. The most cited was AIDS in 56.7% of cases. Television and radio were leading all sources of information on STDs 30%. 94% of participants said that sexual intercourse is a risky behavior for STD transmission. 60% of participants knew the HIV transmission pathways. 89% of participants said that persons who have sex with anyone are a high-risk person. 80% of participants knew method of STDs prevention and the use of Condoms mentioned by 82% of participants. Urethral discharge as a sign of STD was mentioned in 58% of cases. Television and radio were leading all sources of condom information 57%. Alone (without any help) came at the top of all sources of knowledge of condom use in 20% of cases. Conclusions: High levels of knowledge about STIs/HIV/AIDS have been found, but despite this good knowledge, risk behaviors remain high.
P7
Diagnosis of tuberculosis in patients infected with HIV from urine: experience of Ngaba (CHME, Ngaba) mother and child referral hospital in Kinshasa, Congo Introduction: To evaluate the contribution of the diagnostic technique for tuberculosis in HIV-infected patients from urine. Material and methods: Cross-sectional study carried out between May and November 2017 among HIV-infected people suspected of having tuberculosis followed by CHME, Ngaba of Kinshasa, Congo. The diagnosis of tuberculosis was made by looking for bacterial antigen lipoarabinomannan through urine (TB lam) and genexpert MTB/RIF from sputum. Results: Out of 132 HIV-positive patients suspected of having tuberculosis, of whom 52% were referred for treatment and general poor condition, 92 were female (69.6%) and the average age was 40.7 years. The detection of Ag Lam in the urine was positive in 88 presumed TB patients (66.6%) whose CD4 count was 174 c/mm 3 (3-699) TBM/RIF genexpert performed on sputum of presumed TB patients with positive Ag LAM returned positive, 90% of cases (n=10), the only case (n=1) with positive genexpert in whom Ag LAM was negative had resistance to rifampicin. Conclusions: The TB LAM test improves the diagnosis of tuberculosis, especially in HIV-infected patients whose clinical condition is advanced and the production of difficult sputum. The use of this test not only allowed a rapid diagnosis of tuberculosis but also promptly start anti-tuberculosis treatment
P8
HIV epidemiology in Tunisia: is it the same for Tunisians and migrants? Introduction: Despite the scale-up of the Human Immunodeficiency Virus (HIV) response, the evolution of its epidemic among the overexposed populations in Tunisia is expanding. Scarcity in data related to these individuals, including migrants, is a major hindrance to the fight against HIV. We aimed to describe the socio-epidemiological features of HIV among both nationals and migrants living in Tunisia. Materials and methods: In a retrospective observational study, we collected socio-demographic and epidemiological data for all newly HIV diagnosed patients enrolled in care in the Infectious Disease Ward of La Rabta Hospital, Tunis. Results: Among 1,151 HIV patients included (median age =34.04 years), 85.49% were Tunisians and 14.51% were migrants. The sex-ratio varied by nationality group (Tunisians M/F=1.97, migrants M/F=0.91). Most migrants came from African countries; 34.13% from Libya and 56.28% from Sub-Saharan Africa. About two thirds of patients lived in the capital area (65.61% of Tunisians, 64.07% of migrants). Unemployment represented 37.88% while sex work was reported in 20 cases only (1.86%). Most students enrolled (n=63) were migrants (66.66%), mainly sub-Saharan Africans (90.48%). Heterosexual contact was the main route of HIV transmission (52.40% of Tunisians, 68.79% of migrants) followed by drug injection (27.48% of Tunisians, 19.86% of migrants). Acquired Immunodeficiency Syndrome (AIDS) was found in 62.06% (63.33% of Tunisians, 54.55% of migrants) and initial CD4 cell count was lower than 200 c/μl in 57.56%. hepatitis B surface antigen (HBs-Ag) was positive in 11.35% whereas testing for hepatitis C antibodies (anti-HCV) revealed 30.00% of reactivity. Loss to follow-up after diagnosis was reported in 28.58%, especially among migrants (47.90%). Mortality rate was 25.46%; 90.58% of deaths were AIDS-related. Conclusions: The HIV epidemiology in Tunisia varies widely between locals and migrants. Thus, an effective fight against HIV should take into account these differences and plan targeted actions. (16 9%), which is a prognostic sign of rapid development of HIV infection in these regions of the country. Western regions remain areas with low and medium levels of incidence of HIV infection. Among the examined respondents concerning to the ways of infection foremost is sexual HIV transmission (heterosexual) -1,205 persons, at the second place is artificial parenteral usage of injecting drugs -739 persons, and at the third place is homosexual -49 persons. Conclusions: After analyzing the results, it is need to pay attention and conduct public educational activity in regions, where it was registered the largest number of AIDS patients and where the highest rates of distribution of this disease are presented. It is also need to pay attention to the leading ways of transmission that can significantly affect on the future of dissemination of the disease. were between 20-44 years old with mean age 33.4 years, 47/322 (14.6%) were migrants, including 5 foreigners diagnosed with HIV-1 in Bulgaria and 42 Bulgarian citizens infected abroad. The prevalent HIV-1 subtype was defined as subtype B 125 (38.8%), followed by CRF01_AE 63 (19.6%), subtype C 22 (6.8%), CRF02_AG 21 (6.5%) and a variety of more than 30 other HIV-1 subtypes, circulating and unique recombinant forms. The global phylogenetic analysis of the prevalent subtypes: B, CRF01_AE and CRF02_AG indicated that they have been introduced in Bulgaria from different countries of the world with possible overflow from different transmission groups. Conclusions: We found high genetic diversity among HET with domination of non-B subtypes and phylogenetic link between sequences isolated in Bulgaria and other countries around the world from different transmission groups. Our results indicated that providing of molecular-epidemiological surveillance of HIV-1 diversity among different transmission groups is of importance to better control HIV-1 epidemic in Bulgaria.
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Misuse of PrEP and atypical HIV seroconversion: about a case Hélène Laroche, Isabelle Poizot-Martin, Carla Cano, Olivia Faucher-Zaegel, Sylvie Bregigeon, Pervenche Martinet, Caroline Solas, Catherine Tamalet Assistance Publique-Hopitaux Marseille, Marseille, France
Introduction: Pre-exposure prophylaxis (PrEP) using tenofovir/ emtricitabine is highly effective for preventing HIV infection. The risk of PrEP misuse and eventual interference with HIV seroconversion should be documented. Materials and methods: We report the case of a 28-year-old MSM who has frequent unprotected sex and recreational drug use (chemsex). He attended a STDs prevention center following diagnosis of gonorrhea in a sexual partner. He presented with weight loss (−2 kg), asthenia, febricula, lymphadenopathy, alopecia and diarrhea since 3 weeks. Last available HIV negative serology was five months old. Results: HIV-1 seroconversion was confirmed on positive serology (ratio 87.51, threshold >1.25) with negative p24 antigen (<3 pg/ml). Western blot displayed only 3 positive bands: p18, p24 and gp16 leading to the diagnosis of a primary HIV infection. However, HIV plasma viral load was low after two different tests (56 copies/mL with VERIS Beckman Coulter test and 1860 copies/mL with the ANRS/ Biocentric assay). These discordant data led us to suspect an undeclared PrEP. Indeed, patient declared a self-medicated PrEP QD for one month without prior HIV-testing. HIV genotyping found a wild type HIV-1 B subtype. A single-tablet formulation with integrase strand transfer inhibitor was preferred to a non-nucleoside reverse transcriptase or protease inhibitor based-regimens in order to avoid drug interactions with recreational drugs reported by patient. Conclusions: This case illustrates that: 1) frequent HIV testing is suitable for PrEPs users, especially when high risk behaviors are documented; 2) 'Wild' PrEP use should be a usual suspect whenever a discordance between serology and virology is observed. Hence, information and close monitoring of putative PrEP users should be provided in order to avoid misdiagnosis. 
Materials and methods:
A serum/plasma samples were obtained from patients from different regions of the country and 696 nucleotide sequences over the of gag-pol HIV-1 genes. Multiple alignment of nucleotide sequences was carried out using the algorithm ClustalW and MAFFT. Phylogenetic trees were constructed using the algorithm ML (maximum likelihood) in the programs PHYML (Phylogenetic maximum likelihood), and GARLI (Genetic Algorithm for Rapid Likelihood Inference), with the model of the replacement of nucleotides GTR + I + G. Results: There were 157 (22.6%) sequences from the city of Minsk, 150 (21.6%) from the Minsk region, 152 (21.8%) from the Gomel region, 114 (16.4%) from the Brest region, 51 (7.3%), from Mogilev -42 (6.0%), from the Vitebsk region -30 (4.3%). 412 (59.2%) of the patients were male and 284 (40.8%) were women. 325 (46.7%) men and 117 (16.8%) women were infected parenterally with the co-administration of drugs, 167 (24%) women and 71 (10.2%) male sexually infected with heterosexual intercourse and 16 (2.3%) of men were MSM. 658 (94.5%) of HIV-infected patients were carriers of HIV_1 A6 subtype, 15 (2.2%) -B, 3 (0.4%) patients -G and C subtypes, 11 (1.6%) -CRF03_AB, 4 (0.6%) -CRF02_AG and 2 (0.3%) -CRF06_cpx. The epidemic process in the territory of the Republic of Belarus is mainly supported by small local outbreaks associated with different variants of HIV A6 subtype. Conclusions: On the territory of the Republic of Belarus, the epidemic process for HIV infection is supported by 'local' variants of HIV-1 subtype A6, there are separate cases of importation of the virus from outside the country. HIV infection has gone beyond the risk groups and is actively spreading in the population of sexually active individuals.
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A case of acute multidrug resistant HIV-1 infection with acquired immunodeficiency syndrome Introduction: Transmission of multidrug resistant HIV, development of AIDS during acute HIV infection and HIV antibody (Ab) seroreversion are uncommon events. Here, we report a case of acute multidrug resistant HIV-1 subtype B infection, who developed rapid deterioration and opportunist diseases. Besides, HIV antibody seroreversion was rapidly observed after early initiation of antiretroviral therapy (ART). Materials and methods: A previously healthy 32-year-old man having high-risk sexual contacts, developed Pneumocystis jiroveci pneumonia, oesophageal and oral mucosal candidiasis and a severe herpes zona infection associated with a cachectic syndrome. A reactive fourth-generation combination antigen/Ab HIV-test led to further analysis including immunoblot assays, RT-PCR and genotyping. Results: HIV viral load was at log10 4,9 copies/mL. Patient CD4 counts were 4 cells/mm 3 . Regarding AIDS indicator conditions and CD4 cell count, patient was classified in category C3 of CDC classification. Nevertheless, seroconversion was incomplete. Immunoblot analysis showed Ab positivity against gp41, p24 and p17 but remained negative for gp120 and p31 specific Ab, strongly suggesting early HIV-1 infection (Fiebig IV). Genotyping confirmed infection by HIV-1 subtype B and showed D67N, T215C, T69D mutations on Reverse Transcriptase that all together may confer reduced susceptibility to NRTI. Genotyping of the protease revealed many mutations among which M46L, A71V, V82A, resulting in reduced susceptibility for all protease inhibitors except darunavir. No resistance mutation was revealed by genotyping Integrase. ART by truvada, darunavir/r and dolutegravir was initiated. In two weeks HIV RNA was under 40 copies/mL and a seroreversion with only persistence of anti-gp41 Ab on immunoblot analysis was observed. Conclusions: We reported here a rare case of AIDS during a multidrug resistant HIV-1 acute infection. The severity of this case reinforces the need to prevent HIV-1 transmission in populations considered at high-risk such as MSM. Introduction: The progress towards the UNAIDS 90-90-90 target are increasingly being reported, especially at national level. However, in many cases, different data sources are being used to calculate each of the 90-90-90. Comprehensive reporting in the public domain of national care continuum drawn from program data is necessary for tracking progress towards the 90-90-90 target. Materials and methods: We searched PubMed, UNAIDS country progress reports, WHO/UNAIDS reports, national surveillance and program reports, PEPFAR Operational Plans, and conference presentations/ abstracts for the 'latest available and comprehensive' national HIV care continua in the public domain. We defined comprehensive as including at least 'On antiretroviral therapy (ART) and Viral suppression' data drawn from national program data. We ranked the described methods for indicators to derive high, medium and low-quality continuum. Results: For 2012-2017, we identified 87 national care continua, representing 28 million (77%) of the 2016 global estimate of people living with HIV (PLHIV). Only six continua (2% of 2016 global HIV burden) were high quality, using standard surveillance methods to derive an overall denominator and program data from national cohorts for estimating steps in the continuum. In the 87 countries, the average proportion of PLHIV on ART was 49%, and Virally suppressed was 40%. Six countries have already achieved the 90-90-90 target. There were significant variations in methods used for national continua and lack of availability of complete continua, especially data on first 90. Conclusions: National continua of care are increasingly available in the public domain but there is wide variation in methods and data sources for determining progress towards 90-90-90. National care continua from Sub-Saharan Africa were limited in number. A standardized public domain monitoring, evaluation and reporting approach could improve the use of scarce resources to achieve 90-90-90 through improved transparency, accountability and efficiency.
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Biological hepatic markers of inflammation and fibrosis following durable sustained virological response to direct acting antiviral agents in HIV/HCV co-infected patients: preliminary results from the cohort driven by the CoReVIH at the UniversityHospital of Clermont-Ferrand, France Introduction: Direct-acting antiviral agents (DAAs) against hepatitis C Virus (HCV) infection is a revolution, achieving, in patients with HIV/HCV co-infection, a rate of sustained virological response (SVR)>95%. The regression of hepatic fibrosis following durable SVR in this subgroup is not clearly documented. We report preliminary results on the evolution of biomarkers of hepatic inflammation and fibrosis in HIV/HCV coinfected patients treated with DAAs. Materials and methods: A cohort of PLWHIV is carried out by the Infectious Diseases Unit at the University Hospital in Clermont-Ferrand, France. Over the 2010-2017 period, 42/130 patients with a HIV/HCV co-infection received DAAs: 31M, median(IQR)age: 50(46-53)y, HCV transmission was injection drug use (50%), heterosexuality (26%), HSM (17%). HCV subtypes were mainly 1a(22), 3a(7) and 4a(6). Before DAAs, 7 had marked fibrosis (F3), 16 had cirrhosis (F4) according to Actitest-Fibrotest. DAA combinations were sofosbuvir-based regimens according to AFEF and EASL consensus. The evolution of hepatic inflammation was assessed by median(IQR) ALAT and ASAT values and hepatic fibrosis by APRI and FIB-4 scores before and after DAAs. Results: All patients (but one) had a SVR after DAAs. No relapse, no CHC, no HBV reactivation but one HCV re-infection and no hepatic failure with clinical issues were identified after DAA therapy (median follow-up (IQR): 27.6(12.9-37.4) months). Among 23/42 patients with a score F3/F4 before DAAs, 19 had a median (IQR) SVR achieving 18.5(9.9-30.1) months (4 F4 patients were under treatment). Initial hepatic inflammation assessed by median(IQR) ALAT and ASAT levels decreased respectively from 74(51-91) to 31(24-35) and from 45(37-51) to 26(19-36) UI/ml. Consistently APRI score decreased from 0.82(0.51) to 0.35(0.27-0.63) and FIB-4 score from 2.22(1.3-6.7) to 1.23(1.1-2.9). Conclusions: A durable SVR folllowing DAAs combination was associated with a significant decrease of biological markers of hepatic inflammation and fibrosis in F3/F4 HIV/HCV co-infected patients.
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European HIV and Hepatitis Testing Week: an opportunity to increase HIV and hepatitis C awareness in testing Edith Barber, Elias Phiri, Emily Cheserem, Monica Lascar, AdamZhi Tong, Denis Onyango Barts Health NHS, London, UK Introduction: There is an estimated 60,162 infected people with hepatitis C (HCV) in London of which 1,791 people are affected in the London Borough of Waltham Forest (LBWF). We explored the impact of a coordinated multiagency approach, government health agencies and local HIV&HCV Non -governmental organisation (NGO) on increasing knowledge about HIV&HCV, and also on uptake of HIV&HCV testing during the European HIV and Hepatitis Testing Week in LBWF. Materials and methods: Three main activities were evaluated: educational activities aimed at increasing HIV&HCV knowledge, transmission and testing among Health Care Professionals (HCP), plus school-based assemblies and workshops; HIV&HCV testing: hospital stalls, mobile bus and at local council premises; media promotion of the campaign: press releases, hospital and Council websites. Results: 30% completed the questionnaires.139 of 142 HCP attended hospital-based lectures, 3 of 142 poorly attended the community-based HCP talk. The lectures improved attendees' knowledge, 16% gave correct answers to post lecture questions. 764 pupils received school-based talks on HIV&HCV transmission and testing. A total of 112 self-testing kits for HIV&HCV were given out; 82 within hospital, 30 on the mobile bus, of which 52 (46%) men and 60 (54%) women, aged between 19-49 years. An additional 46 kits were given out at the local council by the NGO. Project was covered by 3 local newspapers and 1 radio-station. Conclusions: Joint partnership between community and hospitalbased services was feasible and productive, reaching 1,018 individuals. Hospital-based educational activities and uptake of self-testing kits for HIV&HCV was greater than similar activities in community-settings. Knowledge gaps in HIV&HCV transmission still existed, even among hospital staff. Knowledge levels increased, with potential benefit to patients. More work is required to understand interventions that can impact engagement in community settings.
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HIV and hepatitis C virus infections and associated risk behaviours among injecting drug users attending a syringe service program: a cross-sectional study in Tunis, Tunisia Amine Ghrabi, Safa Zaied, Jihène Khadija Turki, Asma Chamakh, Sirine Bel Haj Taieb, Samir Bouarrouj Tunisian Association of Information and Orientation on AIDS and Toxicomany (ATIOST), Tunis, Tunisia Introduction: People who inject drugs (PWID) frequently engage in high risk behaviors exposing them to human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection. This study aimed to assess injection and sexual risk behaviors among a sample of PWID attending a syringe service program (SSP) in Tunis, Tunisia. -37 Materials and methods: A cross-sectional sample of 113 PWID attending SSP for HIV prevention inTunis was selected from September 2017 through February 2018. All consenting participants completed a questionnaire-based interview followed with tests for anti-HIV and anti-HCV. Results: Mean age was 39 years (IQR 32-47) and mean duration of injection drug use was 11 years (0-29). Most participants were men (96%), unemployed (69%), and had less than a high school diploma (97%). The prevalence of HIV and HCV infection was 10% and 80% respectively. During the past 12 months, 45% reported receptive syringe sharing and 71% reported re-using syringes. PWID with longer duration of injection drug use (>5 years) were more likely to be HCV-infected (87% vs. 54%; p<0.001). HCV-infected PWID were more likely to engage in receptive syringe sharing compared with uninfected PWID (52% vs. 22%; p=0.01). Having non-regular sexual partners during the past 12 months was reported by 35% of PWID, and 77% of these had not used a condom consistently with this type of partners. Younger PWID (≤35 years) were more likely to have non-regular sexual partners compared with older PWID (51% vs. 26%; p=0.009). Conclusions: High-risk behaviors are very frequent among PWID attending SSP in Tunis. Coupling expanded SSP coverage with HIV/HCV prevention education could reduce risky behaviors and prevent new infections among current PWID.
POSTER PRESENTATIONS
Journal of Virus Eradication 2018; 4 (Supplement 1): 1
P18
The levels of hyaluronic acid in different HIV-infected patient groups 
Riga Stradins University, Latvia
Introduction: Chronic hepatitis C (HCV) is the most common coinfection in HIV infected patients, affecting more than half of HIV patients. One of serum biomarkers for detection of hepatic fibrosis is hyaluronic acid (HA), which increase in serum is enhanced by development of liver fibrosis. The aim of the study was to evaluate the level of HA in HIV infected patients with and without HCV, and possible coherence of HA with CD4 cell count, HIV RNA load, HIV stage and existing antiretroviral therapy (ART). Material and methods: Totally 100 HIV infected patients were enrolled in the study and divided in groups depending on presence of HCV: 56 patients with HCV and 45 without HCV. Additionally, patients were grouped according to HIV stage, presence of ART. Statistical analysis was performed by using IBM SPSS 23.0 nonparametric methods. Results: Statistically significant difference of HA levels was found between groups with HCV (M=52.01±66.63 ng/ml) and without HCV (M=21.40±22.65 ng/ml), p=0.003. There was no statistically significant correlation between HA level and CD4 cell count and between HA and HIV-RNA load. The level of HA was significantly lower at HIV stage A in comparison with stage B, U=99.0, p<0.05, and stage C, U=362.5, p<0.01. There were no significant differences of HA levels between stage B and stage C, U=235.5, p=0.92. Statistically significant difference of HA levels was found between NNRTI therapy group and no therapy group (U=351,50, p<0,05) Conclusions: The results obtained from our study does not demonstrate any influence of CD4 cell count and HIV RNA viral load on hepatic fibrosis marker-HA, though HIV stage B and C is associated with higher HA levels. Patients on ART containing NNRTI show lower HA levels, this finding suggests that NNRTI has possibly protective effect on development of liver fibrosis.
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Plasma levels of bacterial LPS and endotoxin antibodies in HIV mono-infected and co-infected with HCV patients IQR=13, 14) , but not statistically significant, p=0,312. No differences were found between groups in regard to LPS and EndoCab IgG. In the total study group negative correlation was found between CD4 count and EndoCab IgG (rs=−0,314, p=0,005); weak and statistically not significant correlation between 160, p=0, 156) . In HIV/HCV group negative correlation was found between CD4 and EndoCab IgG level 497, p=0, 004); 339, p=0, 05) . No statistically significant correlations between CD4 count, LPS and EndoCab antibodies was found in HIV monoinfected group. No effect of HIV treatment was found on LPS or EndoCab levels in any of study groups. Conclusions: Increased levels of EndoCab antibodies as well as correlation with CD4+ cell count in HIV/HCV group could suggest enhanced bacterial translocation and systemic immune activation in HIV/HCV coinfected patients.
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Epidemiological and economic evaluations according to DAA treatment access: an interim evaluation based on PITER cohort data Results: In 2014 -2015 in 2016, 4,090 patients (41% in F0-F2 stage) and in 2017, 1,066 patients (70% in F0-F2 stage) . Mean age: 58+−12 years, 55% were male; genotype 1b was prevalent (55-60%). Standardising the real-life data of the three enrolment periods in 1,000 patients, the investment on DAAs was considered 15 million euros during 2014-2016 and 9 million euros in 2017. For each of the 2014-2015, 2016 and 2017 enrolment periods the estimated payback periods were 11.5, 10.5 and 8.5 years respectively. The total cost saving after 20 years was 24.0, 29.9 and 24.7 million euros for 1,000 patients treated during 2014-2015, 2016 and 2017 respectively. Conclusions: The epidemiologic pattern of patients in care in Italy has changed following the universal access to DAA treatment. This study could be a useful tool for public decision-makers in understanding how HCV epidemiological profiles influence the HCV liver disease economic burden.
P21
Performance evaluation of new automated VIDAS anti-HEV immunoassay tests superinfection of HBsAg+ carriers generally progresses to chronicity. The diagnosis of HDV infection is generally based on the demonstration of HDV antibodies (HDV-Ab) in HBsAg+ individuals. Serum HDV-RNA can be recognized in most chronic HBsAg+ carriers with reactive HDV-Ab. Information on the rate and clinical relevance of HDV-Ab in persons with markers of resolved HBV infection is rather scarce. Presumably, this population should reflect past acute dual coinfection episodes. However, some of these individuals may present with elevated liver enzymes and/or significant hepatic fibrosis, opening the question for the existence of HBsAg-seronegative occult HDV infections. Material and methods: Specimens with markers of past HBV infection, namely positive anti-HBc and/or anti-HBs using commercial tests, were selected. Individuals with HBsAg+ were excluded. Serum HDV-Ab was tested using a commercial ELISA. In HDV-Ab reactive samples, serum HDV-RNA was tested by PCR. Results: A total of 406 sera with markers of resolved HBV infection were identified. Twenty (4.9%) were HDV-Ab+ but none was HDV-RNA+. Two thirds of specimens had been collected from injection drug users. Overall, 57 (14%) were HIV+ whereas 203 (50%) were anti-HCV+. All HDV-Ab+ patients but one were HCV-Ab+. Twelve had been successfully treated for chronic hepatitis C and 2 had cleared HCV spontaneously. Four subjects displayed elevated liver enzymes, of whom 3 had chronic hepatitis C and one admitted high alcohol intake. Conclusions: Active hepatitis delta was not recognized in patients with HDV-Ab+ and markers of past HBV exposure. These results reinforce the notion of a self-limited outcome following dual acute HBV and HDV co-infection, supporting the current policy of excluding hepatitis delta only in HBsAg+ individuals. Introduction: Viral hepatitis is the seventh leading cause of death in the world, half of it is attributed to the hepatitis C virus (HCV). In Tunisia, the impact of HCV is considerable. In 2006, more than two-thirds of HCV carriers would progress to cirrhosis and hepato cellular carcinoma. The aim was to describe the epidemiological evolution of the carriage of anti-HCV antibodies in a population of soldiers and to establish a map of HCV in Tunisia. Materials and methods: We realised a seroprevalence study, between 2003 and 2012, based on data on the anti-HCV antibody test carried out for all soldiers during national service or during military recruitment. The study was comprehensive including all young, male, apparently healthy and from all parts of Tunisia. The screening was carried out by third generation and fourth generation ELISA tests then validated by Immunoblot. Results: Our population was 175,322 young male adults. The average age was 22.59±2.26 years. They were under age 25 in 82.32% of cases. The average of the subjects screened was 17,532 each year. The detected prevalence of carriage of anti-HCV Ab was 0.11%. From 2003 to 2012, the lowest tested prevalence was 0.07% in 2004 and the highest was 0.17% in 2011. There was no significant increase or decrease in the prevalence of Anti-HCV Ab during the study period when measuring evolution trends by the Spearman correlation test (r=0.857, p=0.564). The region with the highest 'estimated prevalence' of carriage of anti-HCV Ab was North-West with a figure of 0.22%. Central-East and South-East had the lowest estimated prevalence at 0.04%. Conclusions: Absence of a decline in HCV prevalence rates was observed. We recommand more prevention such as the reinforcement POSTER PRESENTATIONS Journal of Virus Eradication 2018; 4 (Supplement 1): 1-37 of actions on the modes of transmission of the virus, the systematization of the screening for every personpre senting a risk factor and the development of a program of taking in charge of people infected with HCV.
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Genotyping and molecular characterization of hepatitis B virus in Belarus Elena Gasich, Vladimir Eremin, Alina Nemira Republican Research and Practical Center for Epidemiology and Microbiology, Minsk, Belarus
Introduction: The successful implementation of the large-scale vaccination campaign against hepatitis B (HBV) in the Republic of Belarus envisaged by vaccinations started from 2000 has significantly reduced the incidence of acute HBV by more than 6 times. At the same time, the significantly reduced incidence of acute HBV in the country's population did not correlate with the incidence rate of chronic HBV (CHBV). An equally important component of the epidemiological surveillance is the pathogen genetic variability evaluation with the results enabling to identify the dominant gene variants in the country and estimate the contribution of each of them to the epidemiological process development. Introduction: To evaluate the behavior, attitude and sexual practice of adolescents and young people infected with HIV. Materials and methods: Cross-sectional and descriptive study conducted between January and June 2017 among adolescents and young people living with HIV, aged between 10 and 24, followed at the Kalembelembe pediatric hospital in Kinshasa/DRC. A standardized, closed questionnaire was submitted face-to-face to adolescents and young people participating in the survey.
Results: Of 94 participants whose average age was 20 years with a sex ratio of 0.4. It was noted that 4.3% were between 10-14 years old, 40.4% between 15-19 years old and 55.3% between 19-24 years old. At the day of the survey, 56 participants (59.6%) were sexually active and the first sexual intercourse occurred between 10-14 years in 2.1% of cases, between 15-19 in 31.3% and between 19-24 years in 66.7%. 24 participants (42.9%) reported having only one partner, 16 (28.6%) between 2 and 5 partners, 12 (21.4%) between 6 and 10 partners and 4 ( 7.1%) more than 10 partners. The use of condoms was systematic in 35.7%, irregular in 50% and never used in 14.3%. Of the 59 female participants, 21 (35.6%) had previously had a pregnancy. Of the 16 documented, two (12.5%) had carried the pregnancy to term and 14 (87.5%) had aborted: An episode of abortion in 7.1% of respondents, two episodes in 57, 1%, three episodes in 14.3%, more than four episodes in 21.4%. In 26.8% of the cases, the respondents had shared their serological status with their sexual partner. Conclusions: More than half of adolescents and young people with HIV have sexual behaviors that increase the risk of infection and infection of their partners. It would be desirable for anthropological, sociological and psychological studies to better understand certain attitudes and behaviors to be carried out in order to contribute to the promotion of the systematic wearing of condoms, the promotion of sharing of serological status and the accessibility of the family planning service.
HIV and hepatitis, from bench to bedside
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The analysis of Th1, Th2, Th9, Th17 and Th22 cytokine profiles during long-term suppression of HIV-1 replication Introduction: As in many other diseases, cytokines play a central role in the pathogenesis of HIV-1 infection. The effect of prolonged suppression of viral replication on their synthesis is insufficiently studied. The aim of this study was to analyze the effect of long-term suppression of HIV-1 replication in period longer than 2 years on cytokine immunity. Materials and methods: Eighty treatment-naive HIV-patients were enrolled in cytokine expression analysis. Plasma concentrations of 13 cytokines were measured in two time points, before the initiation of antiretroviral therapy and after a minimum of 2 years of continuous viral suppression by using a multiplex bead-based flow cytometry assay (Human Th1/Th2/Th9/Th17/Th22 13plex Kit FlowCytomix). Results: Plasma concentrations of selected cytokines before initiation of antiretroviral therapy were: IFN-γ (median 16.7 pg/ml, range 0-966.7 pg/ml), IL-1β (38.0; 0-753.7), IL-2 (34.1; 0-571.6), IL-4 (77.6; 0-409.4), ), IL-6 (1.9; 0-266.6), IL-9 (29.6; 0-508.7), IL-10 (11.2; 0-377), IL-12 p70 (3.7; 0-168.2), IL-13 (67.1; 0-482.2), IL-17A (30.5; 0-296.5), IL-22 (127.6; 0-1815.8) and . After a minimum of 2 years of viral suppression the obtained plasma concentrations of cytokines were: IFN-γ (median 9.2 pg/ml, range 0-766.5 pg/ml), , IL-2 (47.9; 0-437.6), IL-4 (45.8; 0-335.1), ), IL-6 (1.1; 0-40.9), ), IL-10 (12.1; 0-938.9), IL-12 p70 (3.4; 0-56.2), IL-13 (42.5; 0-531.8), IL-17A (20.3; 0-238.1), IL-22 (156.5; 0-1453.9) and TNF-α (7.2; 0-879.2). Concentration of IL-17A was significantly decreased in therapy-naive patients compared to HIV-1 negative controls (Fisher's exact test, p=0.03). The differences in the concentration of cytokines between two time points were not statistically significant. Conclusions: Our study shows that the long-term suppression of HIV-1 replication has no effect on the plasma concentration of selected cytokines.
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Genome characterization of HIV-2 biological clones with divergent replication capacities Introduction: HIV-2 variants from asymptomatic, aviremic individuals replicate slower than variants from individuals who progress to AIDS, suggesting an association between in vitro replication capacity and disease progression similar to what is known for HIV-1. We have generated and characterized complete genomes of aviremic and progressor HIV-2 biological clones with divergent replication capacities to identify potential viral factors that may correlate to biological phenotype. We have also assessed the genetic diversity of the HIV-2 LTRs and their association with the replication capacities of these clones. Materials and methods: HIV-2 biological clones were isolated by co-cultivation of patient PBMC with CD8-depleted healthy donor PBMC in limiting dilution. Genomic DNA was isolated from cells infected with slow, intermediate or fast-replicating clones. HIV-2 genomes were amplifed and sequenced by Sanger method. For the LTR-transactivation assays, 293T cells were co-transfected with variant HIV-2 5'LTR-luciferase plasmid constructs and Tat-expression plasmids. Results: Whole genome molecular characterization of these HIV-2 variants did not reveal any evidence of recombination. Virus sequences showed no G-A hypermutation and no differences in GC content. The in vitro transcription assays demonstrated that all HIV-2 clone LTRs are functional promoters with a low basal transcriptional activity and are responsive to Tat protein-mediated transactivation. Variation in transactivation did not differ significantly between slow-replicating and intermediate/fast-replicating clones (p≥0.1), using a standard Tat protein.
Conclusions: Possible causes for the divergent in-vitro replication capacities of these clones remain unclear. Our results demonstrate that there are no major differences in viral factors that may be associated with spontaneous viral supression in aviremic HIV-2-infected individuals. The lack of discernable differences in viral factors indirectly points to a role for host immune responses.
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Introduction: Kaposi's disease remains the most common neoplasia in AIDS. Objectives: Epidemiological, para-clinical and evolutionary analysis of 30 cases of Kaposi's disease. Materials and methods: A retrospective study of 30 cases of patients living with HIV who presented Kaposi 's disease collected from January 2000 to June 30, 2017. Results: Patients aged from 23 to 60 with an average age of 40 +/− 3 years including 2/3 men. Heterosexuality is the mode of transmission as noted with 66.6% of cases, followed by 10% of cases of homosexuality. HIV seropositivity revealed Kaposi's disease in 50% of cases. The mean CD4 cell count was 73.2/mm 3 in our series. Mucocutaneous location is notified in 76.6% of cases, and in 13.3% visceral (lung 6.6%, gastroduodenal 6.6%) and the skin in 10%. The biopsy confirmed the diagnosis in 30% of cases (23% skin, gastroduodenal 7%). Opportunistic infections were associated in 43% of cases, dominated by tuberculosis 16.6%, esophageal candidiasis oral 10%, cryptococcal meningitis 6.6%, 6.6% and minor salmonellosis pneumocystis pneumonia in 3.3% of cases. Two cases of HBV co-infection are noted. Four male patients had a systemic form (mucocutaneous and gastrointestinal involvement 2 cases, mucocutaneous and gastroduodenal reached 2 cases). None of our patients received anti-cancer chemotherapy, 90% received antiretroviral treatment, and 10% were not eligible for treatment due to advanced disease and non-compliance. The evolution marked by 11 deaths secondary to severe pneumonia tables 6 cases visceral localization 4 cases, 1 case polymyositis broadcasts. The outcome was favorable in 2/3 of cases, however, there is a case lost. Conclusions: This work highlights the importance of early diagnosis, the impact of gravity location objectifying interest of chemotherapy associated with antiretroviral therapy.
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Fanconi syndrome induced by tenofovir in HIV patients
Mounira Rai, Amel Ouyahia, Abdelkader Gasmi, Wahiba Guenifi, Abdelmadjid Lacheheb Faculty of Medicine, Setif, Algeria Introduction: Tenofovir disoproxil fumarate (TDF) is a nucleotide reverse transcriptase inhibitor. It is currently the treatment of choice for patients co-infected with human immunodeficiency virus (HIV) and hepatitis B virus. Its antiretroviral efficacy and good tolerance are responsible for the higher frequency of prescriptions compared with other nucleoside analogs. However, it can induce acute renal toxicity causing impairment of the proximal tubular function of the kidney. This is highly dependent on factors such as preexisting renal insufficiency, low body weight, or presence of associated diabetes Materials and methods: We report a case of Fanconi syndrome associated with the use of tenofovir disoproxil fumarate. A 67-year-old HIV-infected woman on follow-up in the Infectious Diseases Hospital of Setif for HIV1 infection since 2004. Her HIV infection was well controlled by antiretroviral therapy; she presented with Fanconi syndrome with acute renal failure three months after starting antiretroviral treatment including tenofovir. Results: Our case illustrates the first case of Fanconi syndrome that occurred in Infectious Diseases Hospital of Setif in a patient infected with HIV-1 and treated with a triple regimen including tenofovir. The overall incidence of renal toxicity including Fanconi syndrome due to tenofovir remains quite rare. Conclusions: This report highlights the need for close monitoring of renal function, calcium and phosphate, proteinuria, and glycosuria in patients treated with antiretroviral drugs, including tenofovir by clinicians.
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Dual agents against HIV and HCMV Introduction: Since the first description of AIDS, coinfections have been part of the clinical presentation and HCMV (human cytomegalovirus) is among the most common opportunistic infections observed in HIV-infected persons. HCMV, a virus that infects people of all ages, is not overly pathogenic in immunocompetent people. However, in HIV-infected individuals, HCMV is associated with a wide range of serious clinical diseases, such as retinitis, pneumonitis, colitis and other end organ disease, as well as with indication of more rapid HIV disease progression and increased occurrence of AIDS-related events. Recently, HCMV has also been associated with a higher risk of HIV transmission. The combined use of antivirals targeting HIV and HCMV may be beneficial both for patients already infected with HIV-1 as well as for prevention of HIV-1 transmission. The development of dual-targeted drugs that combine anti-HIV-1 activity and anti-copathogen activity constitutes a new step in therapeutic strategy. Potentially such drugs may be less toxic than combinations of several compounds. Materials and methods: Compounds were synthesized starting from corresponding 1-[ω-(4-bromophenoxy)alkyl]uracil derivatives and 2',3'-dideoxy-3'-azidothymidine (AZT). Stability of compounds was studied in the presence of different esterases. Results: Here we present new conjugates of non-nucleoside HCMV replication inhibitors and AZT, a classical nucleoside inhibitor of DNA biosynthesis, catalyzed by HIV reverse transcriptase. Conclusions: The proposed conjugates are depot forms and will be hydrolyzed by the action of cellular enzymes, releasing components that have high antiviral activity. The creation of these molecules will improve both the solubility of non-nucleoside inhibitors and the pharmacokinetic parameters of the modified nucleoside. Algeria from January 1986 to June 2017. Data were collected and analyzed by epi info 7.
Results: 550 HIV+ patients, 60.5% were males. Mean age was 38.9 and 38.4 years for males and females respectively. 54.6% of males and 67.6% of females were married. 11.7% male patients were migrant workers, 27.7% currently unemployed, 87.5% females were housewives. Heterosexual contact was the commonest mode of transmission (82.6%). Unprotected extramarital sex by husband is the most source of infection. 91.8% of married men have sexual relationships outside marriage, as compared to 0.0% for married women. Among married couples, 72.4% of males had HIV+ wives, whereas 94.4% of females had HIV+; 16.9% of males were not aware of the HIV status of their wives and among females 6.1% did not know the HIV status of the husband. 89.2% of males were diagnosed before their wives. Among female, 62.9% had diagnosis of disease first among their husbands. 15.3% females had already lost their husbands in comparison with males where 1.4% of them had lost their wives. Diagnosis was late in 62.4% and 42.6% for male and females respectively. The most common opportunistic infection was PJP (16.4%); 89.8% females were on ARV in comparison with males (81.9%); HIV mortality rates were higher for men (32.2%) than women (18.1%).
Conclusions: A higher female prevalence of HIV infection might be expected in Algeria due to high-risk behavior among men (unprotected extramarital sex). Most of female had no independent income. Initial diagnosis was earlier in the case of the husband. The hight rates of deaths can be explained by delay in diagnosis.
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Adherence to aniretroviral treatment and knowledge on HIV/AIDS among the people living with HIV in Armenia Tatevik Balayan National Center for Disease Control and Prevention, Yerevan, Armenia Introduction: Antiretroviral therapy (ART) stops the progression of HIV infection and prevents HIV transmission. Successful treatment depends on the level of adherence to ART. We aimed to identify the association between the ART adherence and the knowledge on HIV/AIDS and ART among the people living with HIV in Armenia.
Material and methods:
We used convenience-sampling approach to recruit 180 study participants. Sample size was calculated using the formula for two equal groups to find a difference in proportions. We used quantitative cross-sectional survey design. Interviews were conducted using structured self-administered questionnaires in 2017. We used 4-item Morisky scale to measure adherence to ART. Descriptive statistics and simple logistic regressions were run using SPSS.
Results: The adherence to ART was 54%. About 53% of the participants thought that HIV infection is curable, 41% of them knew that ART has many side effects, 86% of the respondents were aware that life expectancy improves when they receive ART and 82% knew that the treatment is not effective if taken irregularly. In unadjusted analysis, no significant associations were found between the ART adherence and the answers to the first two knowledge questions (1. HIV is curable, 2. AR has many side effects). In unadjusted analysis, those who knew that the life expectancy improves when they receive ART had 3 times higher odds of being adherent to ART (OR 3.08, 95% CI 1.26-7.52) compared to those who did not know. Those who knew that the treatment is not effective when taken irregularly had about 2 times higher odds of being adherent to ART compared to those who didn't know (OR 2.40, 95% CI 1.20-5.24).
Conclusions:
The results suggest the need for educational programs to increase the knowledge on HIV/AIDS and antiretroviral treatment. Further studies will help to explore determinants of adherence to ART in depth.
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The usefulness of an annual medical check-up in people living with HIV: a French multicenter experience Introduction: The need for novel method to prevent human immunodeficiency (HIV) infection has become an urgent global publich health priority. In sub-saharan Africa (SSA), 57% of all people infected with HIV are women and girls. The need for new female-initiated microbicides that prevent HIV infection could provide an important tool to control the HIV/AIDS epidemic. Regions heavily affected include those of low income with already stretched scarce resources for clinical management. These areas are often lacking in research experience and microbicides expertise. Materials and methods: Criteria used by Access/Nestra Klinikal to identify sites are: HIV prevalence and incidence; population and community characteristics: investigator interest: ability to develop physical research infrastructure; ability to conduct research according to internationally approved guidelines; regulatory and ethical environments; and the availability or the ability to build clinical support structures for trial participants. Results: Selection and development of sites for clinical trials should be undertaken in a comprehensive fashion to create an effective research environment that includes regulatory, scientific and political/ community concerns. Site selection and development for large muilti-center efficacy varies. Conclusions: Site selection by sponsors is best archieved in collaboration with local researchers familiar with the communities who can provide comprehensive strategic plans for individual site development. Early involvment of host country representatives may enhance product registration following pivotal efficacy trials. Results: A total of 15,233 HIV infected mothers and their 15,404 exposed infants aged 6 weeks to 18 months were recruited. Mean age of infants was 16.7 weeks, and 34.8% were breastfed. Mean age of mothers was 27.5 years. The overall rate of transmission was 9.4%. No gender was associated to MTCT. Only 3.8% of infants were HIV infected when their mothers underwent ART treatment compared to 25.9% when they did not. As well, only 4.1% of infant were infected under Nevirapine prophylaxis, compared to 26.4% when no Nevirapine was given to the infant. Infection rate increased with infant 'age at testing. The younger age of the mother also favors the transmission (p=0.003). There were more infected children in singlet pregnancies compared to multiple pregnancies, p<0.001. The order of delivery in twin's pregnancies did not impact MTCT. There were more HIV infected children in male-female twins' sets (p=0.037) Conclusions: In our setting, taking altogether much effort is needed to reduce vertical transmission of HIV. Our results prove the efficiency of ART in mothers as well as ARV prophylaxis in infants in the reduction of MTCT. The mother and infant age and the feeding option also impact the transmission of HIV. These findings suggest that many parameters contribute to MTCT of HIV-1. Interventions to decrease MTCT of HIV through family planning and regular pre/post natal consultations and good clinical practices should be re-enforced. . 228 individuals were included, for which a compendium of behavioral and epidemiological data was carried out. A clinical and biological follow-up at 1 month and every 3 months including an STD and renal assessment was prescribed. Results: 228 males and MSM were included in the study. 30% were under the age of 29, 61% were between 30 and 49 years old and 9% over 50 years old. 75% declared that they did not use any psycho-active substances. The side effects of PrEP were limited to 7% digestive disorders and 1% cephalgias. No HIV or hepatitis B seroconversions were observed. 2 patients had acute hepatitis C, including 1 with a co-infection hepatitis A that required the cessation of PrEP. 4 acute hepatitis A were diagnosed. Among the 228 MSM, 17 showed Syphilis, 40 had Gonorrhea, 33 Chlamydiae and 10 with a Lymphogranuloma Venereal. There were a total of 123 episodes of treated STDs (17 Syphilis, 56 Gonorrhea, 40 Chlamydiae, 10 LGV). It was also noted that PrEP increased immunization coverage for hepatitis A (0/33%) and hepatitis B (64/83%). Conclusions: PrEP-HIV is a well-tolerated prophylaxis. No HIV seroconversion was detected over this period. The prevalence of STDs in PrEP is difficult to compare to the pravalence of STDs in non-PrEP, due to different behavioral and sexual practices. The challenge of extra-hospital CeGIDD will be to reduce the number of STDs to come, to insist again and again on prevention and screening with close follow-up.
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Knowledge regarding human immune deficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) in a French hospital Introduction: On World AIDS day 2017, a survey regarding HIV and AIDS was conducted in our hospital. The principal aim of the study was to assess HIV knowledge in order to drive awareness of HIV transmission, prevention and treatment. Materials and methods: The survey was conducted by healthcare professionals. The questionnaire consisted of eleven items. Data included respondents' demography (sex, age, occupation i.e. healthcare professional), knowledge of HIV epidemiology, transmission, prevention and treatment. They were collected in the multiple-choice questionnaire and analyzed with Microsoft Excel. Results: We analyzed 107 responses. Among these, 66 came from healthcare professionals. For 13% of healthcare professional respondents and 32% of the other respondents, there is no difference distinction between HIV and AIDS. The data also suggests that people are generally aware of HIV transmission and prevention. It is well known that HIV is spread mainly by having sex with (97%) or sharing drug injection equipment with someone who has HIV (77%) and that the correct use of condom reduce the risk of HIV infection (98%). But a significant gap in knowledge persists, notably about AIDS testing and the course to follow a risk behaviour. The testing sites were well known (laboratory, hospital, health center), except the in-home HIV test known for less than half of the respondents. 60% of healthcare professionals and 55% of the other respondents were knowledgeable about post-exposure treatment. 3% of healthcare professionals didn't know the procedure to follow after a risk behaviour. The importance and the efficiency of treatment were well known even if 5% of the general population still wrongly believes that antiretroviral therapy can cure HIV infection. Only 78% of healthcare professionals and 57% of the other respondents know that HIV treatment is a lifetime treatment. Conclusions: This survey was an opportunity to improve the knowledge of HIV among the general population even with healthcare professionals.
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Acceptance of HIV self-testing in DR Congo: results from a questionnaire survey Introduction: Many countries affected by the burden of HIV have decided to implement HIV self-testing, a strategy designed to reach the UNAIDS target of 90% of people worldwide HIV-tested by 2020. Despite some challenges, HIV self-testing is easily accessible and cost-effective, particularly regarding the human, material and financial considerations. Those who test positive are advised to go to the health facility for appropriate healthcare. Materials and methods: We conducted a voluntary survey in French with 40 young people living in Beni city, North Kivu, DR Congo. Data was entered into an Excel database. Results: All 40 persons completed the questionnaire in full. Average age of respondents was 31 years old (range 18-46 years). Males represented 50% of the sample. Marital status was 55% single and 45% married. The majority (97.5%) was employed, 60% were health workers, and 35% were students (secondary school or university). Over three-quarters (77.5%) of the respondents agreed to enroll for the self-test, and 72.5% were able to pay the test fees if required. 27.5% noted that the self-test is less expensive than the test at the dedicated test facilities. The self-test was perceived as very advantageous for the following reasons: Discretion (58%), rapid result (90%). Reported disadvantages included technical difficulties of self-test (22.5%), fears about a false result (22.5%), emotional distress if the test is HIV positive (27.5%), and fear of suicide (7.5%). 10% also fear the risk of intentional propagation of HIV by persons who test positive.
Following a negative result, most respondents (60%) said that they would keep using preventive measures against HIV and other sexual communicable diseases. Others (17.5%) said they would follow the instructions to repeat the test in 3-6 months. Conclusions: Most respondents regarded the HIV self-test favorably. Reported advantages are discretion and the rapid result. Main concerns are possible technical difficulties and emotional distress.
P45
Counselling volunteer testing nocturnal anonymous in MSM HIV and syphilis in the population at risk MSM: case of 2AVIE in Togo Adjété Ayaovi Anoumou Alliance Action Vie (2AVIE), Lomé, Togo Introduction: The ALLIANCE ACTION VIE Association carries out voluntary HIV and syphilis screening activities. Peer educators (EPs) distribute free screening vouchers and MSM come to take their test within the association. We organized nocturnal campaigns on our premises, giving results on the spot, then, to reach more people, campaigns on sites (maquis, bars, dance halls and train stations). The goal for us is to touch more MSM, many want to do the tests but will not move and go to them is more motivating. Materials and methods: We work with the mobile HIV prevention and testing unit 2AVIE. PEs select the sites most frequented by MSM and also at the request of MSM. The 2AVIE Screening Committee team has trained two MSM facilitators who administer the pre-and post-test questionnaires. The screening is done with the tests Determines HIV and Syphilis and SD Bio line, the test is open to everyone, even without good, the PE distribute good and stick discrete distinctives on them. These identifiers allow a good reference at the time of the test run for MSM. We had eleven releases in three months. Results: We reached 613 MSM. All were screened and received their results. Of these tests, 08 were positive for HIV and 02 for Syphilis and on the spot they had their first dose of syphilitic treatment and an appointment was made for the second and third dose. HIV positive cases are in the active file of the association. Conclusions: This method has had an impact: The number of MSM screened has increased considerably because in six months in fixed strategy we reached 165 MSM while with this method we touched in three months 613, in addition to other networks make us call to organize screening campaigns in their site. MSM have selected other sites and ask us to organize screening actions in them. This being a pilot phase, we intend to organize other actions in other sites.
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Barriers to HIV testing in health care facilities, knowledge, attitude and practice of healthcare providers in the country of Georgia Introduction: Georgia is a small country with HIV prevalence less than 0.5%. There is universal access to HIV treatment and care; however 50% of all HIV infected persons are not diagnosed until late in their infection. In order to evaluate the knowledge, attitude and practice of health care providers and barriers to HIV testing, we surveyed health care providers to develop recommendations for improving the current strategies for HIV testing in health care facilities in Georgia. Materials and methods: Anonymous interviews were conducted by 330 randomly sampled physicians from June 1 to November 30, 2016. Data were analyzed by R software.
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Results: Mean age of physician respondents was 43; 71% (234) were women with the mean work experience of 19 years. 44% (144) reported having received training on HIV and 87.5% (289) were aware of the national free HIV testing program. 79% (261) of providers reported that in their clinical settings HIV testing is performed. Clinical symptoms of HIV/AIDS were correctly identified by 35% (114) and 16% (52) did not know the means of HIV transmission. Disclosure of patients HIV status to ensure physicians safety was considered mandatory by 84% (277). Respondents 32% (106) considered stigma, 48% (157) lack of information and 58% (190) financial resources, governmental and administrative support as barriers for HIV testing.
Conclusions:
The main barriers include: low level of knowledge on HIV testing, treatment and prophylactic strategies; poor motivation; HIV related stigma among health care workers; lack of HIV training and insufficient financial support. We suggest the need to improve HIV testing performance in health care facilities, in order to increase the early diagnosis and effective treatment of HIV patients, education of health care providers concerning the importance of screening for early diagnosis and treatment to preserve the health of HIV patients and prevent transmission is critically needed.
